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 The melanocyte: general biology 
1 Structural and functional aspects 
1.1 The melanocyte: key player of the epidermal melanin unit 
In vivo, the pigment producing cell, known as the melanocyte, resides in the basal layer of mammalian epidermis 
(see Figure 1) in a multicellular association with approximately 36 viable keratinocytes (Fitzpatrick and 
Breathnach, 1963). Within this so-called functional epidermal melanin unit (EMU) the melanocyte synthesizes, 
transports and transfers the pigment melanin to its surrounding keratinocytes (Quevedo et al., 1975). The various 
amounts and types of melanins (see p.14) in the recipient keratinocytes significantly determine the color of 
mammalian skin and hair. 
 
 
Figure 1. Representation of the epidermal melanin unit (EMU). A melanocyte resides in the stratum basale of the epidermis. In normal skin 
approximately every tenth cell, anchored on the basement membrane, is a melanocyte. Melanosomes are transferred from the melanocyte into 
surrounding keratinocytes of the EMU. Keratinocyte stem cells (stratum basale) divide and daughter cells undergo terminal differentiation while 
being pushed upwards in the different epidermal layers. The dermo-epidermal junction consists of an undulating basement membrane that 
adheres the dermis to the epidermis (adapted from ‘Dermatology’, chapter 65: Biology of melanocytes, by Bolognia & Orlow, 2003). 
 
Pigmentation of the skin has important evolutionary and physiological implications with photoprotection of 
underlying tissues from ultraviolet (UV)-induced DNA damage being the most valuable function (Hill, 1992). It has 
been shown that eumelanins (see p.14) not only function as ‘sunscreen’ but that other properties, like anti-oxidant 
and free radical scavenging, are also important in cell and tissue protection (Prota, 1994; Kobayashi et al., 1995). 
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1.2 The melanosome: a unique pigment cell-specific organelle 
The melanosome is a unique melanocytic organelle in which melanin is synthesized and deposited. Melanosomes 
undergo a well-defined, sequential, multistep maturation process. The melanosome is a hybrid organelle that 
initiates from the fusion of premelanosomes, originating from the smooth endoplasmic reticulum (SER), and 
tyrosinase-loaded vesicles, budding off from the trans-Golgi network (TGN). This dual vesicular origin is known as 
the bipartite theory of melanosome biogenesis (Jimbow et al., 1976; Kushimoto et al., 2001; Basrur et al., 2003). 
These so-called stage I (pre)melanosomes transform into elongated, fibrillar organelles which are tyrosinase-
positive (stage II melanosomes). From here on melanin biosynthesis begins and pigment granules are uniformly 
deposited onto intralumenal fibrillic structures, giving the melanosome a darkened striated appearance (stage III 
melanosomes). In heavily pigmented melanocytes, melanin synthesis and deposition continues until no 
intralumenal structural details can be seen (stage IV melanosomes) (Seiji et al., 1963; Hearing, 2005). During and 
following this maturation process, melanosomes are transported from their site of origin (perinuclear cytosplasm), 
through elongated processes, called dendrites, towards the dendritic tips of the melanocyte. The process is 
necessary for the subsequent transfer to keratinocytes in the EMU. This intracellular organelle translocation 
process relies on several molecular motor proteins in close association with the microfilament (actin) and 
microtubule (tubulin) cytoskeleton (reviewed in Lambert et al., 1999; Westbroek et al., 2001). Long-range 
anterograde melanosome transport (perinuclear to peripheral) along the microtubules is mediated by the motor 
protein kinesin and is an ATP-hydrolysis driven process (Vancoillie et al., 2000b; Hara et al., 2000). Kinesin binds 
directly to kinectin which is a melanosomal membrane-associated protein and believed to be a receptor for 
kinesin (Vancoillie et al., 2000c). The retrograde movement of melanosomes (peripheral to perinuclear) is 
mediated by the motor protein dynein that can bind the protein complex dynactin which is associated on the 
melanosomal membrane (Vancoillie et al., 2000a). Melanocytic dendrites consist of a central microtubule core 
surrounded by a subcortical actin network (Lacour et al., 1992). In order to obtain a correct peripheral 
melanosome distribution, a ‘cooperative delivery and capture’ model was proposed (Wu et al., 1998). The motor 
protein-mediated (kinesin and dynein) melanosome transport back-and-forth the microtubule cytoskeleton in the 
dendrites is followed at the appropriate time by melanosome capture into the subcortical actin network by the F-
actin associated motor protein myosin Va (Lambert et al., 1998). It was shown that only myosin Va isoforms 
containing exon F were able to perform this process in melanocytes, and that a tight tripartite protein complex 
between myosin Va (containing exon F), melanophilin and Rab27a (the latter being a GTP-binding protein and 
present on the melanosomal membrane) was necessary to mediate this translocation (Westbroek et al., 2003). 
Mutations in myosin Va and in Rab27a were shown to impair this melanosome transport (Bahadoran et al., 2003), 
causing pigmentary dilution as found in Griscelli syndrome type 1 (GS1; Pastural et al., 1997) and type 2 (GS2; 
Menashe et al., 2000) patients, respectively. After melanosomes are captured in the peripheral dendritic 
subcortical actin network, they must be transferred to the surrounding epidermal keratinocytes, where they form 
supranuclear melanin caps (Sulaimon and Kitchell, 2003). Much less is known about the molecular events 
regulating this process. Several hypotheses have been proposed and several approaches have been established 
to monitor the transfer process (Berens et al., 2005). The cytophagocytosis theory states that a melanocytic cell 
part, being the tip of a melanocyte dendrite or filopodium containing melanosomes, is pinched off and 
phagocytosed by a keratinocyte (Okazaki et al., 1976; Yamamoto and Bhawan, 1994). The discharge theory 
describes melanin release in the extracellular space by exocytosis (fusion of melanosomal membrane and 
melanocyte plasma membrane). Subsequent melanin is taken up by the recipient keratinocyte by phagocytosis 
(Virador et al., 2002). The fusion theory defines fusion of both keratinocyte and melanocyte plasma membranes 
forming a tunnel structure through which transport of melanosomes occurs (Scott et al., 2002). Finally, direct 
inoculation of melanosomes in keratinocytes has been proposed. 
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2 Melanocyte development and proliferation 
In human embryos neural crest migration is complete by 7 weeks and melanoblasts, the neural-crest derived 
melanocyte precursors, start to appear in the dermis (Zimmerman and Becker, 1959). Shortly after, they migrate 
into the epidermis to their final location on the basal membrane of the basal epithelial layer of the epidermis 
(dermo-epidermal junction; Mayer, 1973). By 10 weeks epidermal melanocytes are observed to have 
premelanosomes (Fujita et al., 1970). The final number and distribution of melanocytes in the epidermis is quite 
constant (Holbrook et al., 1988). The developmental proces (migration and differentiation) of the melanocyte 
lineage is strictly controlled and most information is discernible based on available mutants (reviewed in Boissy 
and Nordlund, 1997; see also p.20). Migration of melanoblasts occurs along the dorsolateral pathway, between 
the somites and ectoderm, and is mainly regulated by (spatiotemporal) action of the KIT ligand / KIT receptor 
complex (reviewed in Yoshida et al., 2001; Kunisada et al., 2001; Wehrle-Haller, 2003). 
Regulation of melanocyte cell growth is mainly controlled by external (keratinocyte-derived) growth factors and 
indicates that a balanced activation of cell surface events is critical for normal melanocyte proliferation and 
development. Peptide growth factors like basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), 
stem cell factor (SCF; KIT ligand), endothelins (EDN) and melanotropins are known mitogens for human 
melanocytes. In vitro, normal human melanocytes require synergistic mitogens in addition to common growth 
factors in order to proliferate. Any disturbance of the normal function of these growth factors and their cognate 
receptors, by elimination due to deletions or mutations or by over-stimulation due to ectopic expression, has a 
direct impact on the number and distribution of melanocytes in vitro and in vivo (Halaban, 2000; see also p.21). 
3 Melanocyte differentiation: cellular, biochemical and molecular aspects 
3.1 The melanin biosynthesis pathway 
Melanins represent a group of complex polymorphous, nitrogenous, multifunctional biopolymers whose function 
vary from camouflage to the quenching of oxidative free radicals after UV light exposure. The two major forms of 
melanin in skin and hair are the brown-black eumelanins and the yellow-red pheomelanins. Both melanins can be 
synthesized and cross-polymerized simultaneously and are known as mixed melanins. Similar to these melanins 
are the brown-black neuromelanins found in deep brain regions. They are by-products of dopamine oxidation 
within neurons and are believed to act as iron sinks (Zecca et al., 2001). A common property of all melanins is 
that several melanin units are linked by strong carbon-carbon (C-C) bonds, but that they differ from one another in 
structural and physical characteristics, as well as chemical composition (Prota, 1995; Ito, 2003). 
The amino acid L-tyrosine is the precursor for the production of all melanins. Being a complex multistep, chemical 
and enzyme-mediated transformation process, the melanin biosynthesis pathway (see Figure 2) initiates with the 
hydroxylation of L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA). This step is obligatory both in vitro and in 
vivo. L-DOPA can also serve as a precursor to both melanins and catecholamines (dopamine, norepinephrine 
and epinephrine), acting along seperate pathways. In the eumelanogenic pathway L-DOPA is oxidized to 
dopaquinone, followed by rearrangements to leucodopachrome and then to dopachrome. A series of 
oxidoreduction reactions leads to the production of the intermediates 5,6-dihydroxyindole-2-carboxylic acid 
(DHICA) and 5,6-dihydroxyindole (DHI). These are then further oxidized to indole-5,6-quinone-2-carboxylic acid 
and indole-5,6-quinone, respectively, and undergo polymerization to form a poorly soluble, brown DHICA-melanin 
and an insoluble, black DHI-melanin, respectively (Prota, 1995; Ito, 2003). 
The eumelanogenic and pheomelanogenic pathway diverge in the dopaquinone step (Prota, 1995). In the latter 
pathway dopaquinone gets conjugated with gluthatione and / or the amino acid L-cysteine to form gluthationyl- 
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and cysteinyldopa, respectively. These intermediates are converted into alanyl-hydroxy-benzothiazine units which 
are then polymerized into soluble, yellow-red pheomelanin. 
 
 
Figure 2. The melanin biosynthesis pathway. Tyrosinase is the key enzyme giving rise to L-3,4-dihydroxyphenylalanine (L-DOPA) and 
dopaquinone, through hydroxylation of the precursor L-tyrosine. Eumelanins are derived from dopachrome metabolites, 5,6-dihydroxyindole (DHI)
and 5,6-dihydroxyindole-2-carboxylic acid (DHICA). The latter compound is sequentially synthesized through action of the enzymes dopachrome 
tautomerase (DCT) or tyrosinase-related protein 2 (TYRP2), and DHICA oxidase or tyrosinase-related protein 1 (TYRP1). Pheomelanins are 
derived from other metabolites in the extra presence of L-cysteine. 
 
3.2 The pigmentary genes and their products: the tyrosinase gene family 
Several genes (127 loci described untill now in mice) are involved directly or indirectly in the regulation of pigment 
production. However, it is beyond the scope of this chapter to describe them all. A complete list of the coat color 
genes in mice and their human homologs can be accessed at http://ifpcs.med.umn.edu/micemut.htm. 
Here we will focus on the genes and their translation products involved in the enzymatic regulation of eu- and 
pheomelanogenesis (see p.14). The tyrosinase gene family includes the genes coding for tyrosinase (TYR), 
tyrosinase related protein 1 (TYRP1; DHICA oxidase) and tyrosinase related protein 2 (TYRP2; dopachrome 
tautomerase or DCT). These gene products show a high degree of homology and share common structural 
domains: (i) an amino-terminal signal sequence important in correct protein processing and intracellular trafficking 
(Oetting et al., 1994), (ii) two cysteine-rich domains of which the first contains an epidermal growth factor (EGF)-
like protein binding region (Jackson et al., 1992; Sturm et al., 1995) which is potentially important in forming a 
functional multiprotein melanogenic enzyme complex within the melanosome (Orlow et al., 1994), (iii) two putative 
copper-binding sites, (iv) a highly hydrophobic transmembrane domain important for anchorage in the 
melanosomal membrane and (v) a short cytoplasmic tail. The latter two domains are important for the correct 
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intracellular targeting of the enzyme and do not play a role in the catalytic function of the enzymes. The initial 
steps in melanin formation, i.e. hydroxylation of L-tyrosine to DOPA (which is the rate-limiting step) and oxidation 
of DOPA to dopaquinone, are mediated by tyrosinase. TYRP1 oxidizes DHICA to quinones and is found distal of 
tyrosinase and TYRP2 in the melanin biosynthetic pathway. TYRP2 mediates the conversion of dopachrome to 
DHICA. More on the transcriptional regulation of these melanogenic genes is shown on p.18. More on genetic 
disorders caused by mutations in genes of the tyrosinase gene family is described on p.20. 
3.3 The melanocyte signal transduction pathways 
The molecular processes involved in the regulation of melanogenesis are centered around two major signal 
transduction pathways: the cyclic AMP (cAMP) pathway and the receptor tyrosine kinase c-KIT / mitogen 
activated protein kinase (MAPK) cascade pathway (see Figure 3). These pathways play a pivotal role in 
regulating expression and / or activity of melanogenic enzymes. Regulation of the expression of melanogenic 
enzymes mainly implies stimulation through a tightly controlled transcriptional mechanism (see p.18). 
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Figure 3. Signal transduction pathways involved in melanogenesis. Two major signal transduction pathways are involved in regulation of 
melanogenesis: the cAMP pathway and the c-KIT / p21Ras / Raf / Mek / Erk pathway. Both pathways can be triggered by extracellular signals 
activating their respective receptors. TRG, tyrosinase-related genes; (i), inactive; (a), active. 
 
The cyclic AMP pathway 
In melanocytes extracellular (melanogenic) stimuli like the pro-opiomelanocortin peptides α-melanocyte 
stimulating hormone (α-MSH) or adrenocorticotropic hormone (ACTH), derived from surrounding epidermal 
keratinocytes, play a pivotal role in melanocyte function. These ligands can bind to the melanocortin-1 receptor 
(MC1R), a seven transmembrane domain receptor coupled to a heterotrimeric Gαs-protein (Barsh, 1996). Upon 
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ligand-receptor complex formation, Gαs-protein activates its downstream effector adenylate cyclase (AC), resulting 
in a significant increase of the intracellular second messenger cyclic AMP (cAMP). The upregulation of 
melanogenesis can be mimicked by pharmacological cAMP elevating agents such as forskolin, cholera toxin (CT) 
or 3-isobutyl-1-mehtylxanthine (IBMX) (Hearing and Tsukamoto, 1991; Englaro et al., 1995). cAMP induces a 
complex set of intracellular interconnected processes of which the activation of cAMP-dependent protein kinase A 
(PKA) is the leading sub-pathway towards melanogenesis (Lalli and Sassone-Corsi, 1994; Bertolotto et al., 1996). 
Phosphorylated (activated) PKA is then translocated to the nucleus where it phosphorylates the cAMP responsive 
element binding protein (CREB) family of transcription factors and CREB binding proteins (CBP). Genes 
containing a consensus CREB responsive element (CRE) sequence in their promotor are direct targets of these 
transcription factors (Karin, 1994). One of those genes is the microphthalmia-induced transcription factor (MITF) 
of which transcription is upregulated in a PKA-dependent fashion. MITF is able to bind to the E-box and M-box 
sequences in the promotor of the melanogenic genes tyrosinase, TYRP1 and TYRP2 (Bertolotto et al., 1998). 
Their increased expression leads to upregulation of melanin biosynthesis. Beyond this above scheme, it has been 
shown that cAMP can regulate melanogenesis through a PKA-independent mechanism. cAMP can inhibit 
phosphatidylinositol-3-kinase (PI3K), resulting in inhibition of protein kinase B (PKB / AKT) phosphorylation and 
activity. Upon PKB inhibition, glycogen synthase kinase 3β (GSK3β) gets dephosphorylated and activated after 
which it is able to phosphorylate MITF on serine 208 (Ser-208), increasing the ability of MITF to bind and 
transactive the tyrosinase promotor (Busca and Bertolotto, 1996; Takeda et al., 2000; Khaled et al., 2002). 
Elevating cAMP levels leads to activation of a complex network of signaling pathways that diverge in cAMP and 
converge to MITF to control melanin synthesis and melanocyte differentiation. 
 
The receptor tyrosine kinase c-KIT / MAP kinase cascade pathway 
The receptor c-KIT plays a pivotal role in melanocyte development and differentiation, illustrated by the fact that 
patients with a heterozygous c-KIT mutation develop a pigmentary disorder with amelanotic skin patches, called 
piebaldism (Spritz et al., 1993). In response to its ligand SCF, c-KIT signaling activates the MAPK cascade and 
triggers two phosphorylation events on MITF. Activated extracellular signal-regulated protein kinase 1 and 2 
(ERK1/2) are translocated to the nucleus where they directly phosphorylate MITF at serine 73 (Ser-73), while 
serine 409 (Ser-409) serves as substrate for p90RSK1 (Wu et al., 2000). This c-KIT-induced dual phosphorylation 
upregulates the transactivational potential of MITF yet simultaneously couples it to proteasome-mediated 
degradation by targeting the protein to ubiquitin-dependent proteolysis. This coupled activation / degradation 
signal seems paradoxical in the regulation of pigmentation. It has been shown that MITF transactivates the 
tyrosinase, TYRP1 and TYRP2 melanogenic gene promotors (Hemesath et al., 1994; Yasumoto et al., 1994; 
Bertolotto et al., 1996, Bertolotto et al., 1998) and that c-KIT stimulation recruits the transcriptional co-activator 
p300/CBP to MITF (Price et al., 1998). Transactivation activity is markedly enhanced by MAPK-mediated 
activation of MITF (Hemesath et al., 1998). However, dominant active and dominant negative p21Ras did not 
increase or reduce pigmentation, respectively (Englaro et al., 1998), despite evidence that c-KIT upregulated 
MITF through ERK1/2 (Hemesath et al., 1998). Probably the same signaling pathway may target MITF for 
activation as well as proteolytic degradation. Homeostatic downregulation is a hallmark of receptor tyrosine kinase 
signaling pathways and occurs at multiple levels including cytokine / receptor internalization, dephosphorylation 
and proteolysis. 
 
Link between two major melanogenesis-regulating signal transduction pathways 
In many cell types, cAMP has been shown to inhibit the MAPK cascade. However, it has been demonstrated in 
B16 mouse melanoma cells and human melanocytes that elevation of cAMP levels activates ERK1/2 (Englaro et 
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al., 1995). This cAMP-dependent activation of ERK1/2 is mediated by the activation of p21Ras and B-RAF kinase, 
and seems to be cell-specific and independent of PKA. However, the classical p21Ras guanine nucleotide 
exchange factors (GEF) Son-of-sevenless (SOS) and Epac are not involved in cAMP-dependent p21Ras 
activation, which suggests the existence of a novel melanocyte-specific cAMP-dependent p21Ras GEF (Busca et 
al., 2000). 
3.4 Transcriptional regulation of melanogenesis  
It is clear that multiple factors, including ubiquitous and cell-type specific factors, have to cooperate to direct 
transcription of the tyrosinase gene family. This provides a good system to study mechanisms for cell-type 
specific gene transcription. Neural-crest derived melanocyte-specific gene expression is tightly controlled by the 
interplay between specific signal transduction pathways (see p.16) and transcription factors. In the center of 
transcriptional regulation of melanocyte differentiation is MITF, a basic helix-loop-helix leucine zipper (bHLH-LZ) 
transcription factor residing in multiple signaling pathways important to the melanocyte-lineage. Heterozygous 
MITF mutations exhibit pigmentary defects due to reduced melanocytes in the skin and hair, a condition known as 
Waardenburg syndrome type 2A (see p.20). The control of expression of melanocyte-specific MITF (MITF-M) is 
regulated by an array of transcription factors that can bind to its promotor (Fuse et al., 1996). CREB and related 
factors confer on the MITF-M promotor responsiveness to cAMP and MC1R signaling (Bertolotto et al., 1998; 
Price et al., 1998). It has been shown that MITF is required but not sufficient to induce melanogenic gene 
expression (Gaggioli et al., 2003). The high-mobility group (HMG) box protein SRY-related HMG-box 10 (SOX10) 
has been shown to bind to the proximal promotor (Lee et al., 2000) and an upstream enhancer of MITF 
(Watanabe et al., 2002) and can cooperate, although not interact, with MITF in activating the TYRP2 promotor 
(Ludwig et al., 2004; Jiao et al., 2004). The paired homeobox domain factor 3 (PAX3) has been shown to regulate 
MITF expression via consensus elements within the MITF promotor (Watanabe et al., 1998; Potterf et al., 2000). 
The lymphoid enhancer factor 1 (LEF1) transcription factor interacts with ß-catenin and enables MITF expression 
to be regulated by Wnt signaling. It cooperates with MITF, through interaction, in the activation of the TYRP2 
promotor (Yasumoto et al., 2002). The human TYR gene contains an enhancer element called the tyrosinase 
distal element (TDE) containing a CATGTG motif at its center and is located 1.8 kb upstream of the transcription 
initiation site. More proximal (-112 to –93), an additional copy of this CATGTG motif is found as tyrosinase 
proximal element (TPE) (Yasumoto et al., 1994). Together with the TDE and TPE, there are two additional 
proximal positive elements, called the M-box (included in the TPE) and the initiator E-box, showing to be the 
binding site for MITF in transactivation of the human TYR promotor (Bentley et al., 1994; Yasumoto et al., 1997). 
A region similar to TDE was found more proximal in the TYRP1 promotor (Yasumoto et al., 1994). The TYRP2 
promotor contains two putative cis-acting elements similar to the M-box and a proximal melanocyte-specific 
promotor (Shibahara et al., 1991). 
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 The melanocyte dysregulated: 
pigmentary disorders 
Mammalian melanogenesis, starting from migration of precursor cells to catabolism of melanin in the skin, is 
summarized in several steps in Table 1. 
 
Table 1. Mammalian melanogenesis (adapted from Sulaimon and Kitchell, 2003). 
Step I Melanoblasts migrate from the neural crest into the epidermis 
Step II Melanoblasts differentiate into melanocytes and undergo clonal expansion in the skin 
Step III Pre(melanosome) matrix formation 
Step IV Melanogenic genes (tyrosinase, tyrosinase related proteins and melanosomal matrix components) induced  
Step IV Tyrosinase and related melanogenic proteins synthesized 
Step V Posttranslational processing and glycosylation of tyrosinase 
Step VI Fusion of vesicles to form melanosomes and initiation of melanogenesis 
Step VII Control of tyrosinase activity 
Step VIII Control of the activity of tyrosinase related protein 
Step IX Modification of melanin 
Step X Melanosome transfer to keratinocytes 
Step XI Melanosome degradation 
Step XII Melanin removal with loss of cornified cell 
 
The major determinant of normal skin color is the quantity and quality of melanin present in epidermal 
keratinocytes and is the resultant of increased melanocyte activity (synthesis, transport, transfer). The density of 
epidermal melanocytes has no influence on constitutive pigmentation. In order to understand the underlying 
etiology and pathophysiology of cutaneous disorders of hypo- and hyperpigmentation, knowledge of structural, 
functional and genetic determinants in development, survival, migration, proliferation and differentiation of 
melanocytes is of crucial importance. Several pigmentary disorders are linked to specifc gene defects, while 
others are the result of imbalances in para- and / or autocrine cytokine networks, or a combination of both. 
However, it is beyond the scope of this chapter to address all disorders of hypo- and / or hyperpigmentation. 
Relevant examples will be given to illustrate the underlying principles and will be largely based on the genetic and 
structural components discussed in the above chapters. 
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1 Genetic disorders of pigmentation 
1.1 Heterogenous (“spotty”) pigmentary defects: impaired melanocyte development 
Pigmentary anomalies that are characterized by a heterogenous distribution of melanin pigments (congenital 
pigment spots) are mostly associated with abnormal distribution of melanocytes during embryological 
development. The receptor tyrosine kinase c-KIT has been shown to be defective in cases of human piebaldism, 
suggesting a role for the SCF / c-KIT signaling pathway (see p.16) to be involved in melanocyte development 
(Giebel and Spritz, 1991). This ligand-receptor complex seems to be crucial for melanocyte survival throughout 
development until late stages of differentiation in the skin (Wehrle-Haller, 2003). Another ligand-receptor system, 
between the endothelin receptor B (EDNRB) and its ligand endothelin-3 (EDN3), is important for early expansion 
and migration of melanoblasts while delaying differentiation (Lahav, 2005). Mutations in EDN3 lead to 
Waardenburg syndrome type IV (WS4) (Edery et al., 1996; Hofstra et al., 1996), while defective EDNRB is the 
cause of Hirschsprung disease (Attie et al., 1995). Two transcription factors have been implicated in the 
development of melanocytes based on either similarity to mouse mutants: MITF, defective in Waardenburg 
syndrome type II (WS2) (Hughes et al., 1994) and PAX3, defective in Waardenburg syndrome type I and III 
(WS1/3) (Tassabehji et al., 1993; Baldwin et al., 1995). In addition to its evident role in melanocyte development, 
MITF also appears to play a critical role in regulating melanocyte function by controlling transcriptional activation 
of the melanogenic genes (see p.15 and p.18). PAX3 seems to be critical for activating melanoblasts and other 
cellular elements to proliferate or to initiate migration from the neural crest (Stuart and Gruss, 1995). 
1.2 Homogenous pigmentary defects: impaired melanocyte function 
Deficient melanin biosynthesis and processing can lead to homogenous increase or reduction of pigmentation 
and is characteristic for genetic disorders of melanocyte function. It is beyond the scope of this chapter to discuss 
them all. Here we will shortly focus on the most common inherited disorders of generalized hypopigmentation 
known to human, of which albinism is the most frequent and well-known (see Table 2).  
 
Table 2. Pigmentary disorders characterized by diffuse pigment dilution in which the gene defect is known. 
Disorder Gene Protein product References 
Oculocutaneous albinism (OCA)    
     type 1A TYR tyrosinase Spritz et al., 1989 
     type 1B TYR tyrosinase Giebel et al., 1991 
     type 2 P P protein Lee et al., 1994 
     type 3 TYRP1 TYRP1 Boissy et al., 1996 
Hermansky-Pudlak syndrome    
     type 1 HPS1 novel protein Fukai et al., 1995 
     type 2 AP3B1 β3A subunit of AP3 Dell’Angelica et al., 1999 
     type 3 HPS3 novel protein Anikster et al., 2001 
     type 4 HPS4 novel protein Suzuki et al., 2002 
     type 5 HPS5 novel protein Zhang et al., 2003 
     type 6 HPS6 novel protein Zhang et al., 2003 
     type 7 DTNBP1 dystrobrevin binding protein 1 Li et al., 2003 
Chediak-Higashi syndrome CHS1 (LYST) novel protein Fukai et al., 1996 
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Table 2. (continued) 
Disorder Gene Protein product References 
Griscelli syndrome    
     type 1 MYOVA myosin Va Pastural et al., 1997 
     type 2 RAB27A RAB27a Menashe et al., 2000 
     type 3 MLPH melanophilin Menashe et al., 2003 
2 Micro-environmental induced pigmentary defects: cytokine network imbalances 
Paracrine melanogenic cytokine networks tightly regulate melanocyte function and the interplay between 
melanocytes and other types of skin cells (keratinocytes and fibroblasts) (Yada et al., 1991; Imokawa et al., 
1998). In vivo, normal melanocyte homeostasis is the result of a fine expression, secretion and interaction 
balance of ligands and their cognate receptors, and subsequent signaling to the nucleus. A distortion in this fine 
balance, due to uncontrolled up- or downregulation of components of the cytokine network, is responsible for the 
constitutive activation or inactivation of melanocytes, which leads to hyperpigmentary or hypopigmentary defects, 
respectively. Many melanogenic paracrine networks exist of which imbalances are associated with distorted 
melanocyte proliferation and epidermal hyperplasia (see Table 3). 
 
Table 3. Pigmentary disorders associated with melanogenic cytokine networks (adapted from Imokawa, 2004). 
hypo- (□) / hyper- (■) 
pigmentary disorder 
melanocyte 
proliferation 
epidermal 
hyperplasia 
intrinsic cytokine or  
chemokine or receptor 
produced by reference 
UVB-melanosis (■) Ç Ç EDN1 / EDNRB / mSCF / c-KIT keratinocyte Imokawa et al., 1995; Hachiya et al., 2001 
UVA-melanosis (■) Ç = GM-CSF keratinocyte Imokawa et al., 1996 
Riehl’s melanosis (■) Ç Ê GRO-α keratinocyte Imokawa et al., 1992 
Lentigo senilis (■) Ç Ê EDN1 / EDNRB / mSCF keratinocyte Kadono et al., 2001; Hattori et al., 2004 
Dermatofibroma (■) Ç Ê sSCF / HGF fibroblast Shishido et al., 2001 
Café-au-lait macule (■) Ç = sSCF / HGF fibroblast Okazaki et al., 2003 
Vitiligo vulgaris (□) È = c-KIT melanocyte Kitamura et al., 2004 
EDN1, endothelin 1; EDNRB, endothelin receptor B; mSCF, membrane-bound stem cell factor; GM-CSF, granulocyte/macrophage colony-
stimulating factor; GRO-α, growth related oncogene-α; sSCF, soluble stem cell factor; HGF, hepatocyte growth factor; Ç, increased; È, 
decreased; Ê, slightly increased; =, unchanged. 
3 Microarray technology in the study of pigmentary defects: usefulness, critical 
considerations and evolution 
Historically pigment cell research has been done one gene at a time. Current advances in molecular biology have 
made it possible to use genome-scale gene expression profile analysis to investigate thousands of genes 
simultaneously. The use of this high-throughput technology enables the discovery of (groups of) genes that are 
associated with a phenotypic difference. The best-known microarrays for gene expression profiling (=mRNA level) 
are the (c)DNA arrays. To accurately assess gene expression differences between normal and pathological 
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states, one should use tissue specimens derived from lesional tissue and compare them with the appropriate 
controls (Chen et al., 2003; Seykora et al., 2003). The use of cell lines or primary culture may be of limited benefit 
in elucidating cutaneous pathophysiology because these cells have been altered by removal from the native 
microenvironment (Seykora et al., 2003). However, all depends on the scientific question one wants to address 
(see chapter 2; Boucneau et al., 2005). As DNA microarrays are empirical screening tools, starting with a specific 
hypothesis is not always necessary. An investigator may perform a pilot experiment without a preconceived 
hypothesis. Following analysis of the initial results, a more discrete hypothesis can be formulated and hypothesis-
driven experiments can be conducted (Dooley et al., 2003). The major critical determinants of a microarray 
experiment are its design, correct analysis and caution during interpretation (Loftus and Pavan, 2000). There are 
several sources of variation in microarray experiments. Biological variation is intrinsic to all organisms and might 
be influenced by genetic and / or environmental factors. Technical variation is introduced during preparation of the 
samples and during the subsequent labeling and hybridization steps. Finally, measurement errors are associated 
with reading the (fluorescent) signals. These sources of variation can be corrected for by using valid statistical 
tests and hence good designs should incorporate replication of experiments both at the biological and technical 
levels. 
Microarrays are in their initial development for clinical application in a variety of tumor models. Melanoma is an 
ideal system to study the genetic changes associated with the stepwise progression of malignancy. It may be 
possible to efficiently screen the entire human genome to identify the particular aberrations in gene expression 
responsible for tumorigenesis in melanoma. Off course these applications can also be valuable tools in the search 
for unique pigmentary defect-associated markers that may be specifically expressed in cutaneous lesions 
(Seykora et al., 2003). The advent of protein-based microarrays allows the global observation of biochemical 
activities on an unprecedented scale, where thousands of proteins can be simultaneously screened for protein-
protein, protein-nucleic acid, and small molecule interactions. This technology holds great potential for basic 
molecular biology research, disease marker identification, toxicological response profiling and pharmaceutical 
target screening (Bertone and Snyder, 2005). Together with gene / protein expression microarrays, which have 
highlighted many potential targets in cancer, tissue microarrays have emerged as a powerful tool to validate these 
targets by measuring tumor-specific protein expression and linking it to clinical outcome (Giltnane and Rimm, 
2004). All these high-throughput technologies are becoming and will become invaluable tools in the molecular 
characterization and classification of all kinds of hypo- and hyperpigmentary disorders, not only in the lab but also 
in the clinic. 
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 Neurofibromatosis type 1 
1 Clinical features and diagnostic criteria 
Neurofibromatosis type 1 (NF1), or von Recklinghausen neurofibromatosis, is a neurocutaneous monogenic 
disorder primarily affecting cells and tissues derived from the neural crest but many other organ systems as well. 
It is one of the most common autosomal dominant tumor predisposition syndromes known to humans with a 
worldwide estimated birth incidence of approximately 1 in 3500 individuals (Poyhonen et al., 1997). The 
pleiotropic NF1 disease manifestations (see Figure 4) result in a mild to severe clinical picture, even within 
families or patients with the same NF1 gene mutation (Friedman, 1999; Gutmann 2001). The clinical diagnostic 
criteria for NF1 are summarized in Table 4. 
 
Table 4. Diagnostic criteria for NF1 (Stumpf et al., 1988; Gutmann et al., 1997). 
The NF1 patient should meet 2 or more of the following criteria 
Six or more café-au-lait macules (prepubertal: diameter ≥ 5 mm; postpubertal: diameter ≥ 15 mm) 
Two or more neurofibromas (nodular and plexiform) 
Multiple inguinal and / or axillary lentigines 
Optic pathway glioma 
Two or more Lisch iris hamartomas  
Distinct osseous lesions (sphenoid dysplasia; thinning long bone cortex with / without pseudoarthrosis) 
First-degree relative (parent, sibling or offspring) who meets the above criteria 
 
Major disease manifestations 
Café-au-lait macules are hyperpigmented patches of the skin that usually occur shortly after birth with a 
prevalence of around 95% in children younger than 1 year old. These hyperpigmentary spots are very striking 
features for NF1 but are not pathognomonic for the disease [see p.32; article I: Pigment-cell related 
manifestations of NF1: an overview]. 
 
Neurofibromas are benign multicellular tumors with a deranged tissue architecture of the peripheral nerves. These 
hamartomatous tumors are composed of several cells (Schwann cells, fibroblast, perineurial cells, endothelial 
cells and mast cells) forming the nerve sheath and excessive deposition of collagenous extracellular matrix 
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(Peltonen et al., 1984; Cichowsky and Jacks, 2001). The cutaneous (dermal) neurofibromas are soft, fleshy 
nodules and involve dermal and epidermal skin. They do not usually develop until preadolescence, with 
increasing tumor load during adolescent and young adult years (Huson, 1988; Riccardi, 1992a; North, 1993). 
Less than 15 percent of children younger than 10 years have cutaneous neurofibromas, compared to 44% in the 
10-19 year age group, 85% of patients between 20-29 years of age, and 94% of adults over the age of 30 (North, 
1993). Early appearance of neurofibromas may give some indication of the future severity of cutaneous 
manifestations for the individual patient; the earlier the onset, the more likely there will be a larger number and 
more extensive distribution of cutaneous neurofibromas (Riccardi, 1992b). In females there is often a clear history 
of an increase in number of neurofibromas during puberty and pregnancy (Dugoff and Sujansky, 1996), with an 
increase during puberty noted in the males. While cutaneous (dermal) neurofibromas may become a major 
cosmetic problem for individuals with NF1, they are not premalignant lesions and do not transform into malignant 
tumors (Gutmann et al., 1997). The subcutaneous (nodular) neurofibromas are more firm and involve peripheral 
nerves in deeper parts of the body. (Diffuse) plexiform neurofibromas occur in approximately 25% of patients with 
NF1 (Huson et al., 1988) and are of significant concern because of the potential for cosmetic disfigurement and 
malignant transformation (Friedman et al., 1999). Large lesions of the head and neck can cause major 
disfigurement and are present in 1-5% of patients. Diffuse plexiform neurofibromas often extend deeply to involve 
all levels of skin, muscle, bone and even viscera. They may cause compression, distortion or overgrowth of 
adjacent structures. Plexiform neurofibromas have a variable natural history in that some lesions may be 
quiescent for long periods. However growth may be aggressive and progressive, especially during infancy and the 
preadolescent / adolescent period. In general they are benign tumours. The value of surgical intervention for 
plexiform neurofibromas has been considered limited because the tumours do not follow tissue planes, are 
difficult to resect, are very vascular, and tend to regrow when incompletely removed. Plexiform neurofibromas, on 
the other hand, are usually congenital in origin and have the potential to undergo malignant transformation into 
malignant peripheral nerve sheath tumors (MPNST). These highly malignant neurofibrosarcomas are exceedingly 
rare in the general population and are a major cause of death in NF1 patients. Estimates of the frequency of 
peripheral nerve malignancy range between 1 and 4% (Huson et al., 1988; Riccardi, 1992b; North, 1993). 
 
Axillary and inguinal freckling is the most useful criteria, after cafe-au-lait spots, for making the diagnosis of NF1 
in young children since freckling tends to appear during the first five years of life, while neurofibromas and Lisch 
nodules may not appear until adolescence. The reported frequency of axillary freckling varies between 64% and 
84% (Huson et al., 1988; Riccardi, 1992b). Inguinal freckling occurs in 52-56% of NF1 individuals (Huson et al., 
1988; North, 1993). More generalized freckling may also occur on the trunk and neck, and in the submammary 
region in women [see p.32; article I: Pigment-cell related manifestations of NF1: an overview]. 
 
Lisch nodules are dome-shaped elevations of the iris surface and are pathognomonic of NF1. They do not cause 
symptoms but are extremely useful as a diagnostic tool, particularly in adults. The incidence of Lisch nodules in 
NF1 increases markedly with age; by the age of five years, around 50% of NF1 patients have Lisch nodules, 
whereas by over 30 years of age, 96-100% of patients have the lesions on slit lamp examination (Lubs et al., 
1991; Ragge, 1993) [see p.32; article I: Pigment-cell related manifestations of NF1: an overview]. 
 
Minor disease manifestations and complications of NF1 
Although not specific enough to warrant inclusion as diagnostic criteria, short stature and macrocephaly are 
common features of NF1. Approximately one-third of patients with NF1 have height at or below the third centile; 
short stature is not usually associated with growth hormone deficiency, abnormalities of the pituitary gland or 
structural skeletal defects. Almost 50% of individuals with NF1 have head circumference at or above the 97th 
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centile. Riccardi found a statistically significant difference between the distribution of height and head 
circumference centiles in patients with NF1 compared to the general population (Riccardi, 1992b). At present the 
mechanisms to account for these features of NF1 are unknown. 
 
Optic pathway gliomas, also called optic nerve gliomas, represent the most common central nervous system 
(CNS) tumor in NF1 and are a specific feature of the disease (Listernick et al., 1997). MRI detects optic pathway 
gliomas in approximately 15% of NF1 patients. However, only 5% of these usually very benign tumors cause 
clinical symptoms (Lewis et al., 1984). Optic gliomas can involve any part of the visual pathway; the intraorbital 
portion of the optic nerves, the chiasm, the intracerebral visual pathways, or any combination thereof. 
Histologically, optic gliomas are low grade astrocytomas, not hamartomas (Alvord and Lofton, 1988) and it is not 
known why some tumors progress rapidly to cause symptoms while others remain quiescent for many years. 
Common symptoms of optic pathway tumours are decreased visual acuity, visual field defects and proptosis; 
other symptoms include optic atrophy, headache, nausea, anorexia and hypothalamic dysfunction (Habiby et al., 
1995). 
 
 
Figure 4. Overview of the clinical / phenotypic features of NF1 [adapted from Powell (1988)]. 
 
Distinctive osseous lesions, e.g. scoliosis, occurs in 12-20% of patients with NF1 (Huson et al., 1988; North, 
1993). The majority of cases of scoliosis in NF1 resemble so-called ‘idiopathic’ scoliosis seen in the general 
population, with a long C-shaped curve involving a significant portion of the spine (up to 10 segments). A second, 
more severe type of scoliosis is seen specifically in NF1, and involves a smaller portion of the spine (less than five 
vertebrae) causing a very sharp, angular curve. This latter form may be associated with a localised area of 
vertebral dysplasia. Vertebral dysplasia may occur in isolation or secondary to a paravertebral neurofibroma; 
these ‘benign’ tumours appear to cause bony destruction, the mechanism of which is unknown (North, 1997). 
Children with NF1 tend to develop scoliosis at a younger age than other children, usually before the age of ten 
years. 
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The other complications of NF1 are individually rare, occurring in less than 5% of patients. These include 
epilepsy, intracranial tumours, hydrocephalus, pseudoarthrosis, sphenoid wing dysplasia, renal artery stenosis, 
and phaeochromocytoma. 
2 NF1 gene structure 
The NF1 gene was isolated by positional cloning and sequenced in the beginning of the 1990s (Cawthon et al., 
1990b; Viskochil et al., 1990; Wallace et al., 1990). Initial linkage analyses mapped the gene to the proximal long 
arm of chromosome 17 and finally narrowed the location further down to about 3 cM of 17q11.2 (Barker et al., 
1987; Goldgar et al., 1989). The gene has long been suspected to encompass approximately 350 kb of genomic 
DNA (Li et al., 1995). However, the latest entry (build 36.1: november 1, 2005) at the NCBI Map Viewer 
(http://www.ncbi.nlm.nih.gov/mapview) shows that the NF1 gene sequence only spans 280 kb. This is mainly due 
to the fact that at full sequencing of the first intron, it was shown that this intron is actually smaller (~60 kb) than 
previously estimated. The gene encodes a mRNA of 11-13 kb containing 59 exons (including alternative splice 
forms; see Figure 5) and is ubiquitously expressed in human tissues. An open reading frame of 8454 bp 
(Bernards et al., 1992; Marchuk et al., 1991) predicts a protein of 2818 aa with a calculated molecular weight of 
327 kDa. Intron 27b contains three functional genes that are transcribed in opposite direction to NF1: OMGP 
(encoding oligodendrocyte-myelin glycoprotein), EVI2B (encoding ecotropic viral insertion site 2 protein B) and 
EVI2A (encoding ecotropic viral insertion site 2 protein A (Cawthon et al., 1990a; Cawthon et al., 1991; Viskochil 
et al., 1991). The AK3 pseudogene lies within intron 37 and is transcribed in the same orientation (Xu et al., 
1992). The NF1 gene promotor is located in a CpG-rich region and does not  
 
Figure 5. The NF1 gene structure. Schematic depiction of the NF1 gene (5’>3’) showing representative exons (drawn in scale) with the known 
alternatively spliced exons (9br, 23a and 48a).The three coding genes (OMGP, EVI2B and EVI2A) inserted in opposite direction in the intron 
between exon 27b and exon 28 of the NF1 gene are shown in green. Three major domains / motifs (CSRD, GRD and NLS) are shown in red. 
 
contain any strong transcriptional start site delineators (TATA / CAAT box). The transcriptional start site precedes 
the translational initiation site and locates 448 bp upstream of the latter. The 3’ end of the NF1 gene is 
approximately 3.5 kb of genomic DNA downstream of exon 49. Several NF1 pseudogenes are scattered across 
the human genome and are thought to arise from duplication and transposition of the NF1 locus (Luijten et al., 
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2000; Luijten et al., 2001). These NF1 related loci (e.g. on chromosome 2, 14 and 22) have been suggested as 
being disease-causing mutation carriers from which mutations can be transferred to the functional NF1 gene on  
chromosome 17 by interchromosomal gene conversion. The high mutation rate of the NF1 gene is one of the 
highest known to humans. Nearly 50% of all NF1 cases represent newly introduced or spontaneous mutations 
without any familial history for NF1 (Huson and Hughes, 1994). The very diverse NF1 mutational spectrum ranges 
from small nonsense and missense mutations over insertions, small deletions and inversions to translocations, 
whole gene deletions and duplications (Messiaen et al., 2001). To date no consistent genotype-phenotype 
correlation has been found in patients in whom the disease mutation has been identified. The exception to this is 
the earlier onset of neurofibromas, occurrence of dysmorphic facial features and intellectual impairment in a 
subset of patients with NF1 with microdeletions that involve the entire NF1 gene and considerable flanking DNA 
(Kayes et al., 1994; Tonsgard et al., 1997). Patients with this NF1 microdeletions also tend to have a substantially 
higher life time risk for developing MPNSTs (De Raedt et al., 2003). 
3 NF1 gene (product) expression 
3.1 NF1 mRNA 
The 11-13 kb NF1 transcript is ubiquitously expressed and has been detected in numerous human (brain, kidney, 
spleen, lung, muscle, neuroblastoma, melanoma, skin fibroblasts, epidermal melanocytes) and mouse (brain, 
kidney, B16 melanoma cells) tissues and cell lines (Wallace et al., 1990; Buchberg et al., 1990; Nishi et al., 1991). 
Different alternatively spliced NF1 mRNA transcripts (see figure 4) are expressed in a developmental- and tissue-
dependent manner. Type I and type II isoforms were characterized first. Type II NF1 mRNA (exon 23a) is the 
most widely expressed transcript and contains an additional 63 nucleotides (nt) which lengthens the GAP-related 
domain (GRD) of the protein product with 21 amino aa (Marchuk et al., 1991). Interestingly, expression of both 
isoforms has been observed to be associated with differentiation status of particular tissues (Nishi et al., 1991). 
Type I predominates in fetal brain and undifferentiated primitive neuroectodermal tumors while type II was 
predominantly expressed in adult brain and differentiated cell lines. In contrast, a higher type I / type II NF1 mRNA 
ratio was found in adult brain (Suzuki et al., 1991). Schwann cell differentiation could be induced by cAMP 
stimulation and was associated with predominant expression of NF1 type II mRNA (Gutmann et al., 1993). The 
type III isoform has an alternatively spliced exon 48a of 54 nt (coding for an additional 18 aa) at the 3’ end of the 
NF1 transcript, downstream of the GRD. Together with NF1 mRNA type IV, which contains both exons 23a and 
48a, the expression of the type III isoform was characterized in muscle (Gutmann et al., 1995; Skuse and 
Cappione, 1997). The isoform (exon 9br, also called 9a) contains an additional 30 nt coding for 10 aa. It has been 
suggested to play a role in differentiation and development of neural tissues of the central nervous system 
(Danglot et al., 1995; Geist and Gutmann, 1996). Several isoforms have been described that are not yet 
confirmed at the protein level. A putative amino-terminal isoform (termed N-isoform 11), about 2.7 kb in length, 
codes for a truncated protein of 593 aa and shares the first 574 amino-terminal residues of the original (type I) 
NF1 gene product, thereby encompassing the first 11 exons. A similar isoform of 551 aa whose amino-terminal 
portion is encoded by the first 10 exons is termed N-isoform 10 (Suzuki et al., 1995). Alternative splicing of exons 
29 and 30 produces three isoforms and omits either one or both exons, introducing a premature stop codon that 
leads to a truncated protein. These isoforms have a tissue-specific expression pattern with the exon 29 skipped 
transcript being expressed only in brain (Park et al., 1998). An amino-terminal isoform, termed NF1-10a-2, has an 
insertion of 45 nt between exon 10a and 10b and showed very low expression in the majority of human tissues. 
Amino acid sequence and motif analysis revealed that the insert coded for a transmembrane segment (Kaufmann 
et al., 2002). 
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3.2 Neurofibromin 
Being an ubiquitously expressed protein, the levels of the NF1 gene product neurofibromin vary in different 
tissues. The protein was identified in all parts of the brain, especially in large projection neurons and Purkinje cells 
(Nordlund et al., 1993). Also strong expression was observed in Schwann cells of peripheral nerves (Nakamura et 
al., 1994). It was also located to keratinocytes and melanocytes in developing rat and human skin (Malhotra and 
Ratner, 1994). Only low levels were detected in cardiac tissues and no neurofibromin was observed in rat skeletal 
muscle, lung and kidney. The NF1 protein has a predicted molecular mass of 327 kDa based on the full length 
size of 2818 aa (Wallace et al., 1990; Marchuk et al., 1991). In gel the apparent size of neurofibromin seems to be 
around 220-250 kDa (Bollag et al., 1991; Gutmann et al., 1991), probably due to specific protein folding during gel 
eletrophoresis. There is no evidence of glycosylation or processing of the full length protein (Gutmann et al., 
1993). The major functional domain in neurofibromin is a central region of about 360 aa (exons 20-27a) (see 
Figure 4) showing marked homology to the catalytic domain of mammalian GTPase-activating protein (GAP) (Xu 
et al., 1990) and yeast IRA1 and IRA2, and is called the GAP-related domain (GRD) which has already been well 
characterized (Scheffzek et al., 1998). Fahsold et al (2000) described a new functional domain upstream of GRD 
on the basis of an unusual clustering of missense mutations identified in a large cohorte of NF1 patients. This 
domain (comprising exons 11-17) seems to coincide with the cysteine / serine rich domain (CSRD) described by 
Izawa et al (1996). This CSRD comprised amino acids 543 – 909 in which three cysteine pairs (suggestive of ATP 
binding) and three potential cAMP-dependent protein kinase A (PKA) recognition sites (obviously phosphorylated 
by PKA) are present. There is reason to believe that a Sec14p-like domain is located downstream of GRD. This 
domain is homologous to the lipid-binding domain of the Saccharomyces cerevisiae phosphatidylinositol transfer 
protein Sec14p, suggesting a possible link between binding of lipids by these proteins and the regulation of Ras 
and Rho GTPases. However, structural divergence in the amino-terminal α-helical region of this domain in 
neurofibromin suggests that only the lipid-binding property may exist and that the phospholipid transfer activity is 
probably lacking (Aravind et al., 1999). Only recently a novel bipartite phospholipid-binding module was 
structurally discovered, composed of a Sec14p-homologous segment and a previously undetected pleckstrin 
homology (PH)-like domain, and showed phospholipid binding (D’Angelo et al., 2006). Further downstream of 
GRD towards the carboxy-terminal domain (CTD) and based on a highly expressed splice variant lacking exon 
43, a functionally active bipartite nuclear localization signal (NLS) was identified which was necesseray and 
sufficient to translocate a NF1-GFP fusion protein (containing the carboxy-terminal part of neurofibromin) to the 
nucleus (Vandenbroucke et al., 2004). 
4 Gene function, molecular interactions and subcellular localization 
4.1 NF1 gene function 
The identification of oncogenes and tumor suppressor genes has made it clear that these genetic components are 
involved in tumorigenesis (Diamandis, 1992). The genetic “two hit” model of tumor suppressor genes has been 
described by Knudson (1971) and has been proposed as one of the several mechanism for tumorigenesis. In this 
model the inactivation of one or both alleles of a tumor suppressor gene is supposed to be involved in the 
development of a particular type of malignancy. NF1 patients have multiple benign tumors that can predispose to 
malignancy. The observation that the central domain of neurofibromin shows sequence homology to the catalytic 
domain of GAP and yeast IRA1 and IRA2 which can downregulate p21Ras activity (Xu et al,1990), suggested that 
the NF1 gene / neurofibromin is a tumor suppressor gene / protein. It is thought to play a crucial role in cAMP-
dependent PKA and p21Ras-associated signaling pathways. Neurofibromin acts as a negative regulator of the 
latter pathway by accelerating the intrinsic GTPase activity of p21Ras, which results in an increased switch of GTP-
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bound, active p21Ras into a GDP-bound, inactive form (Bollag and McCormick, 1991; see also Figure 2). The 
regulation of this molecular switch plays a critical role in the control of cellular growth and differentiation. 
Hyperactivation, due to activating mutations or distorted regulation of p21Ras activity, can lead to aberrant 
signaling for cell proliferation and are involved in the genesis of many human (malignant) tumors (Bos, 1989). 
Several studies have shown that neurofibromin may regulate the cAMP / PKA pathway (Guo et al., 2000; Tong et 
al., 2002; see Figure 6). In Drosophila melanogaster and mice it was shown that neurofibromin regulates the 
activity of AC. More critical clues to the biological function of neurofibromin are provided by studies on the 
subcellular localization, and molecular associations and interaction partners. 
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Figure 6. The interactions of neurofibromin with different functional signal transduction pathways. In addition to its function as a negative 
regulator of p21Ras (Ras-GAP), the NF1 gene product may also be acquired in the regulation of cAMP- and PKA mediated gene transcription 
(Guo et al., 2000) and cytoskeletal changes. Recently, the NF1 tumor suppressor has been shown to be a critical regulator of the TSC2 – mTOR 
signal transduction pathway regulating cellular proliferation and differentiation (Johanessen et al., 2005). 
 
 
4.2 Molecular interactions and subcellular localization 
Neurofibromin has been shown to associate with the three major cytoskeletal systems. The first discovered 
association was with the microtubule cytoskeleton. The association with tubulin was shown to inhibit the p21Ras-
GAP activity of neurofibromin. The critical residues for this interaction reside in the GRD (Gregory et al., 1993; 
Bollag et al., 1993; Xu et al., 1997). Partial clues to its putative function have also been given by the interaction of 
neurofibromin with components of the microfilament (actin) cytoskeleton. Li et al (2001) demonstrated in 
telencephalic neurons and astroblasts that a differential subcellular targeting of neurofibromin towards the actin or 
Chapter 1 | Introduction 
 
30 
microtubule cytoskeleton depends on the developmental status. Heterozygosity at the NF1 gene locus was shown 
to result in aberrant cell attachment and increased cell motility due to actin cytoskeletal abnormalities (Gutmann et 
al., 2001). Similarily in a recent study, Ozawa et al (2005) showed that RNA interference-induced NF1 gene 
silencing enhanced cell motility and dynamically regulated actin cytoskeletal reorganization. An association of 
neurofibromin with the intermediate type filamentous (keratin) cytoskeleton in cultured differentiating epidermal 
keratinocytes was suggested to control the organization of the cytoskeleton during the formation of desmosomal 
cellular contacts (Koivunen et al., 2000; Koivunen et al., 2002). Malminen et al (2002) also demonstrated that 
neurofibromin, through its association with cytokeratin 14, may function in the regulation of epidermal 
histogenesis via the control of the keratin cytoskeleton during assembly of (hemi)desmosomes. Closely related to 
the cytoskeleton is the association of neurofibromin with the motor protein kinesin-1, which has been shown to 
transport protein complexes, organelles and mRNA to specific destinations in a ATP- and microtubular dependent 
fashion. This association, identified by purification of a particulate core-complex that also contained neurofibromin 
2 (merlin), suggests a role for both tumor suppressor proteins in microtubule-mediated intracellular signal 
transduction pathways and vesicular cargo transport (Hakimi et al., 2002). 
Using yeast-two-hybrid analysis Hsueh et al (2001) identified syndecan-2 as cellular interacting protein of 
neurofibromin. Syndecan-2 is member of the transmembrane family of heparan sulfate proteoglycans on the cell 
surface (Carey, 1997). They suggested that this interaction might be a potential mechanism for the membrane 
association of neurofibromin to specialized domains in the plasma membrane. This association might contribute 
to synaptic p21Ras-GAP activity or function in an adhesion-signaling complex at the cell surface. 
The protein NG,NG-dimethylarginine dimethylaminohydrolase (DDAH) that is known as a cellular nitrogen oxide 
(NO) / nitrogen oxide synthase (NOS) regulator has been identified as neurofibromin-associating protein. The 
DDAH-binding regions of neurofibromin were located in the CTD and the CSRD. They were found to coincidently 
contain the sites for PKA phosphorylation. DDAH increased PKA phosphorylation of native neurofibromin 
suggesting that PKA accessibility of neurofibromin is regulated via DDAH interaction and might modulate both the 
cAMP / PKA-related signals and the Ras-associated signals of neurofibromin (Tokuo et al., 2001).  
The same group discovered a novel cellular neurofibromin-associating protein, 14-3-3, which belongs to a highly 
conserved family of proteins that regulate intracellular signal transduction events. 14-3-3 functions as a 
chaperone by regulating catalytic activities, protein-protein interactions and subcellular localization of bound 
proteins (Feng et al., 2004). The interaction is mainly directed to the CTD of neurofibromin. They also showed that 
PKA-induced phosphorylation of neurofibromin enhanced the interaction with 14-3-3 and suppressed the binding 
activity of neurofibromin to p21Ras-GTP. 
Four potential caveolin binding domains have been found in the primary structure of neurofibromin and that this 
interaction modulates p21Ras, Akt and focal adhesion kinase (Boyanapalli et al., 2006). Caveolins have been 
shown to bind a growing number of signaling molecules within cholesterol-rich lipid raft microdomains 
(Sargiacomo et al., 1995). 
If we overview the subcellular localization of neurofibromin based on known molecular interactions, protein motifs 
and domains, it is obvious that neurofibromin is located to a variety of subcellular compartments in different cell 
types. Primarily neurofibromin is found in membrane and cytosolic (particulate) fractions, while a few studies 
(together with the identification of a bipartite NLS in exon 43) have shown a nuclear localization (Daston et al., 
1992; Golubic et al., 1992; Koivunen et al., 2000; Vandenbroucke et al., 2004). An association has been 
described with the plasma membrane (Boyer et al., 1994; Malhotra and Ratner, 1994), the smooth endoplasmic 
reticulum (SER) in neurons (Nordlund et al., 1993) and mitochondria (Roudebush et al., 1997).  
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5 Role of the micro-environment in NF1 etiopathogenesis 
Haploinsufficiency of NF1 (=a situation in which the total level of a gene product produced by the cell is about half 
of the normal level and that is not sufficient to permit the cell to function normally) in the tumor microenvironment 
is becoming increasingly appreciated to have a role in tumor progression. In mouse models, it has been shown 
that a deletion of both copies of the Nf1 gene (Nf1-/-) in Schwann cells (using a Krox 20-Cre promotor to induce 
Schwann-cell specific somatic inactivation of Nf1) combined with Nf1 heterozygosity (Nf1+/-) of the tumor 
microenvironment (fibroblasts, endothelial cells, perineurial cells, mast cells) promoted neurofibroma formation. 
This system could be used as a model for the study of heterotypic cell interactions (Zhu et al., 2002). The 
Schwann cell was confirmed to be the cell of origin in the development of (plexiform) neurofibromas. In NF1 
patients and mice with a germline knockout of one Nf1 allele, all of the cells in the body are heterozygous for NF1, 
raising the question of whether heterozygous neighbouring cells can promote tumor growth more efficiently than 
wild-type neighbouring cells. Implicit is the possibility that heterozygous inactivation of Nf1 has functional 
consequences (haploinsufficiency). It was shown that homozygous Nf1 mutant (Nf1-/-) Schwann cells secrete 
large amounts of KitL (Kit ligand or SCF or mast cell growth factor), stimulating mast cell migration and infiltration 
in the neurofibroma. These Nf1+/- mast cells were shown to be hypermotile in response to KitL and their increased 
cell migration was linked to hyperactivation of the Ras-class IA-PI3K-Rac2 pathway (Yang et al., 2003). Increased 
activation of this pathway was also shown to be responsible for increased proliferation and survival of Nf1+/- mast 
cells (Ingram et al., 2001). 
Whether this model for heterotypic cell interactions is applicable on other cardinal features of NF1, like the 
hyperpigmentary CALMs is currently unknown but is an interesting path for further investigation. Initial studies 
have seen that cultured dermal fibroblasts of normal and CALM skin of NF1 patients secrete higher levels of SCF 
and HGF, and that dermal mast cell numbers are increased (Okazaki et al., 2003; see chapter 1 – article II; see 
General discussion and future perspectives p.126). 
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 The melanocyte and Neurofibromatosis type 1: 
pigmentary defects 
  
 
Article I 
 
Pigment cell-related manifestations in neurofibromatosis type 1: an overview. 
 
Sofie De Schepper #, Joachim Boucneau #, Jo Lambert, Ludwine Messiaen and Jean-Marie Naeyaert. 
Pigment Cell Res 18(1): p.13-24 (2005) (# first two authors equally contributed). 
 
In this review we give a detailed overview of the pigmentary defects in Neurofibromatosis type 1 (NF1). The 
hyperpigmentary anomalies that are observed and described as cardinal clinical features of NF1 can be divided in 
two major groups based on the involvment of the cutis: (i) the cutaneous hyperpigmentary defects (including café-
au-lait macules [CALM] and intertriginous ephelides) and (ii) the non-cutaneous defects (including iris Lisch 
nodules). In overviewing these hyperpigmentary anomalies it becomes clear that the melanocyte is playing a key 
role in the etiopathology of these lesions. We address several hypotheses of CALM etiopathogenesis and finally 
draw attention to a readily seen phenomenon of an increased incidence of melanoma in NF1 patients: a mere 
coincidence or is more going on? 
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  
 
Article II 
 
Café-au-lait spots of Neurofibromatosis type 1 patients and healthy controls: hyperpigmentation of a 
different kind? 
 
Sofie De Schepper, Joachim Boucneau, Yves Vander Haeghen, Ludwine Messiaen, Jean-Marie Naeyaert and Jo 
Lambert. Arch Dermatol Res 297(10): p.439-449 (2006). 
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 Goal of the thesis 
In Neurofibromatosis type 1 patients the NF1 gene is mutated. Several cardinal features of NF1 comprise 
cutaneous and non-cutaneous pigmentary defects (see chapter 1 – article I) which could argue for a specific role 
of neurofibromin in regulation of melanocyte function / homeostasis. The major goal of this study was to gain 
more insight into the functional role of the NF1 gene and its corresponding gene product in primary human 
epidermal melanocytes. To achieve this goal the following research objectives were proposed: 
 
• A (high throughput) gene / mRNA level approach: 
Addressing the effects of NF1 heterozygosity on total gene expression of primary human epidermal 
melanocytes: towards functional analysis of the NF1 gene. 
 
By using a high-throughput transcriptome expression analysis via cDNA microarray technology, we tried 
to establish information on the role of the NF1 gene by looking into a human NF1 heterozygous (NF1+/-) 
melanocytic cell system. Moreover, this is the first analysis of its kind in primary human epidermal 
melanocytes with haploinsufficient expression of the NF1 gene locus. The specific experimental setup 
enabled us to look for differentially modulated genes that were expressed in a genotype (NF1+/+ vs. 
NF1+/-) and / or lesional type (normally pigmented versus hyperpigmented CALM skin) dependent 
fashion. This objective was a first (indirect) attempt to learn more about the role of the wild type NF1 
gene and its product neurofibromin in the regulation of melanocyte biology. The results of this study are 
described and discussed in chapter 2. 
 
• A RNA interference (RNAi)-mediated approach: 
Analyzing the effects of endogenous neurofibromin suppression on proliferation and cell cycle 
distribution of primary human epidermal melanocytes. 
 
Via RNA intereference (RNAi)-mediated knock-down of endogenous NF1 gene (product) levels we 
analysed the effects on melanocyte proliferation and cell cycle distribution. Chapter 3 reports the results 
of this study. 
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• A (subcellular) protein level approach: 
Investigation of the intracellular localization and association of neurofibromin with a new interaction 
partner in primary human epidermal melanocytes. 
 
Via yeast two hybrid, co-immunoprecipitation and subcellular / ultrastructural analysis a new 
neurofibromin interaction partner was identified in epidermal melanocytes, namely amyloid precursor 
protein (APP). Both constituents were shown to colocalize with melanosomes. This subcellular 
localization / association was abrogated in an NF1 heterozygous background. The results of this 
subcellular localization study are described in chapter 4. 
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Gene expression profiling of cultured human NF1 heterozygous (NF1+/-) melanocytes reveals 
downregulation of a transcriptional cis-regulatory network mediating activation of the melanocyte-
specific dopachrome tautomerase (DCT) gene. 
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RNAi-mediated suppression of endogenous neurofibromin does not modulate ERK1/2 phosphorylation or 
the cell cycle in cultured primary human epidermal melanocytes. 
 
Joachim Boucneau1, Sofie De Schepper1, Mireille Van Gele1, Jean-Marie Naeyaert1 and Jo Lambert1. 
(article in preparation) 
 
1 Department of Dermatology, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium 
 
 
Summary 
Neurofibromin, gene product of the NF1 tumor suppressor gene, has been assigned a role in the regulation of cell 
proliferation as its central GTPase-activating protein (GAP)-related domain (GRD) is able to inhibit p21Ras 
activation. This results in subsequent inhibition of cell proliferation, manifested through cell cycle arrest. Via 
siRNA-mediated RNA interference (RNAi), we have investigated the effects of suppression of endogenous 
neurofibromin on cell cycle distribution and proliferative capacities of primary human epidermal melanocytes. We 
did not observe any changes in the proportion of melanocytes reaching the S and / or G2/M phase of the cell 
cycle, nor did we find any changes in cell proliferation in NF1 gene-silenced melanocytes. Furthermore, ERK 
phosphorylation (downstream p21Ras effector) did not increase upon neurofibromin suppression, nor did cyclin D1 
expression. Our data demonstrates that neurofibromin does not seem to play a major role in cell cycle regulation 
in human epidermal melanocytes, at least in vitro and that p21Ras signaling, at least in part, is intact in these cells. 
 
Key words: cell cycle, melanocyte, neurofibromin, proliferation, siRNA 
 
Introduction 
The human NF1 gene is located on chromosome 17q11.2 (Viskochil et al., 1993) and encodes a large 2818 aa 
protein, called neurofibromin (DeClue et al., 1991; Gutmann et al., 1991). Sequence analysis of neurofibromin 
revealed that a central region of around 360 aa shows significant sequence homology to the known catalytic 
domains of the mammalian p21Ras GTPase-activating protein p120GAP, which interacts with p21Ras, promotes 
hydrolysis of p21Ras-bound GTP (active form) to GDP (inactive form) and results in inactivation of the p21Ras 
protein (Xu et al., 1990). Accordingly, loss and / or mutations of neurofibromin elevate p21Ras activity and are 
followed by activation of various p21Ras effectors. (Hyper)activation of p21Ras has been considered to be the 
causative event for tumor formation and other clinical manifestations in e.g. Neurofibromatosis type 1 (NF1) 
patients (Cichowski and Jacks, 2001). In three neurofibrosarcoma cell lines with decreased neurofibromin levels 
an increase in GTP-bound, activated p21Ras was observed (Basu et al., 1992; DeClue et al., 1992). In cultured 
melanocytes from NF1 patients (with a 50% reduction of neurofibromin levels due to haplo-insufficiency of the 
NF1 gene locus) no altered p21Ras-GTP levels could be observed (Griesser et al., 1995). Control of the cell 
division cycle is at the heart of many biological processes in which inactivation of critical cell cycle regulators 
leads to uncontrolled cell proliferation and tumorigenesis. In primary rat Schwann cell cultures from Nf1-/- dorsal 
root ganglia an increased expression of the proto-oncogene cyclin D1 was observed, which is a positive regulator 
of the cell cycle promoting transition from the resting G1 phase into the DNA synthesizing S phase (Kim et al., 
2001).  
In order to further elucidate the role of neurofibromin, we decided to reduce the expression of the NF1 gene and 
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its corresponding gene product neurofibromin by applying RNA interference in cultured primary human epidermal 
melanocytes. In a next step, the effects of NF1 gene silencing on cell cycle distribution and cell proliferation were 
analyzed in this study. 
 
Results 
As neurofibromin is known as a tumor suppressor protein involved in regulation of cell proliferation through 
negative regulation of p21Ras activity, we wanted to examine the role of the NF1 tumor suppressor gene (product) 
in cell growth. We attempted to reduce the expression of neurofibromin in primary human epidermal melanocytes 
by an RNAi-based strategy. After introduction of a siRNA duplex targeting the boundary of exon 44 and exon 45 
of the NF1 gene, the endogenous NF1 mRNA levels as detected by qPCR were significantly reduced to 13% of 
baseline levels by day 2, but then slightly increased again to ~50% of baseline levels at day 8 (see figure 1a). The 
corresponding neurofibromin levels as detected by western blot analysis (using NF1(D) sc-67 and NF1(N) sc-68 
antibodies) dropped equally fast down to 50%-40% of the baseline levels after 2 days and even further down to 
only 15% at day 4, remaining so until day 8 (see figure 1b). The levels of phosphorylated ERK1/2 (indicative for 
an increased MAPK pathway) and cyclin D1 did not change upon neurofibromin suppression. Using the MTS cell 
proliferation assay, no differences in cell proliferation were observed when neurofibromin was suppressed in 
epidermal melanocytes compared to siSCRAMBLE electroporated control melanocytes (see figure 1c), even after 
omission of growth factors (data not shown). As tight regulation of cell division, culminating in two daughter cells, 
is an important determinant of cell proliferation, we analysed the cell cycle distribution of epidermal melanocytes 
after suppression of neurofibromin levels (see figure 1d). Using flow cytometric analysis, the results show no 
significant increased proportion of melanocytes in the S and / or G2 phases of the cell cycle upon neurofibromin 
depletion. However, a clear drop increase in G1 and concomitant decrease in S and G2 phase were observed 
probably due to increasing growth arrest caused by a rise in cell culture confluency over the 8 day time period. 
The results suggest that functional neurofibromin does not regulate the transitions from G1 to S as well as from G2 
to M phase of the cell cycle, at least in epidermal melanocytes. 
 
Discussion 
In this study we present the effects of reduced neurofibromin on the proliferative capacities and cell cycle 
distribution of primary human epidermal melanocytes. We have used the RNA interference technology to knock-
down the endogenous expression of NF1 mRNA and its corresponding protein product. Other tumor suppressor 
proteins like p53 and retinoblastoma are known to be involved in negative regulation of cell cycle, halting cells to 
enter the S phase (Galderisi et al., 2003). Moreover, it has been shown that cooperativity between mutations in 
Nf1 and p53 prolongs sympathetic neuron survival and proliferation (Vogel and Parada, 1998) or gives cell growth 
advantage to mice astrocytes (Bajenaru et al., 2001). Several lines of evidence have indicated that p120GAP and 
neurofibromin regulate p21Ras differently despite their common p21Ras-GAP activity (Bollag and McCormick, 
1991). It has already been suggested that neurofibromin might not be the major regulator of the p21Ras pathway. 
In cultured melanocytes from NF1 patients no altered p21Ras-GTP levels could be observed indicating that 
melanocytes are capable of regulating their levels independently of the NF1 gene defects (Griesser et al., 1995). 
If neurofibromin suppresses cell growth by arresting cells in G0 or G1, its expression might be regulated in a cell 
cycle-dependent fashion. Neurofibromin expression in RAT-1A rat fibroblasts was shown to be upregulated after 
contact inhibition-induced G0/G1 growth arrest, while it did not show any changes when cells progressed through 
the cell cycle. This indicates that neurofibromin expression is a late event associated with cell growth arrest which 
may contribute to maintenance of the differentiated state (Norton et al., 1996). However, in cultured epidermal 
melanocytes from NF1 patients, decreased neurofibromin levels were shown to increase cell doubling times 
(indicative for decreased cell proliferation) and to induce differentiation in comparison to those from normal 
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patients (Kaufmann et al., 1991). An explanation for this paradoxical growth disadvantage in cultured NF1 
melanocytes is currently unknown. Perhaps melanocytes belong to the group of neural crest cells where 
differentiation rather than proliferation is induced by p21Ras activation (Guerrero et al., 1986). However, some 
groups did not demonstrate any induction of proliferation or differentiation in cultured NF1 melanocytes (Abdel-
Malek et al., 1993). This is in accordance to the results demonstrated in our study where we have silenced 
endogenous neurofibromin levels of normal epidermal melanocytes and did not see any changes in cell 
proliferation. In vivo however, an increase in the epidermal melanocyte population is found in NF1 patients 
compared to normal controls (Frenk and Marazzi, 1984; own observations), which suggests that probably 
impaired micro-environmental cues, cellular interactions and / or tissue organization are responsible for increased 
melanocyte proliferation and differentiation in NF1 skin. 
In our study we have suppressed the endogenous expression levels of neurofibromin in normal human epidermal 
melanocytes and demonstrated that transient reduction of the NF1 gene product does not give any growth 
advantage to melanocytes monocultures nor does it significantly change the proportion of cells reaching the S 
and G2/M phase of the cell cycle. These results suggest that the function of neurofibromin is not limited to the 
regulation of the cell cycle, at least in human epidermal melanocytes. Melanocyte cultures prove to be a valuable 
system for molecular biological studies on the function of the NF1 gene (product). The use of in vivo mimicking 
co-culture systems in a two-dimensional or three-dimensional setting could further help in elucidating the interplay 
between (defective) neurofibromin and the micro-environment. This would teach us more on the relevant role of 
neurofibromin in proliferation and differentiation of normal human epidermal melanocytes in the skin. 
 
Material & Methods 
Human primary epidermal melanocyte cultures were established as described previously (Naeyaert et al., 1991; 
Boucneau et al., 2005). Human primary dermal fibroblasts were cultured in DMEM (Invitrogen, Carlsbad, CA, 
USA) supplemented with 10% FCS. A 25-base NF1-specific STEALTHTM siRNA duplex (Invitrogen, Carlsbad, CA, 
USA) (5’-GCGCUGCUUCUUACUGUUC-UAGCUA-3’ and its complement) and a siRNA scrambled control were 
used (5’-GCACAGUAAGA-GUGACGUCACGAUU-3’ and its complement). 100-500 nM duplex was 
electroporated into primary epidermal melanocytes and dermal fibroblasts using the Neonatal Normal Human 
Epidermal Melanocytes kit (NHEM-Neo) and Neonatal Normal Human Dermal Fibroblast kit (NHEM, respectively 
(Amaxa, Germany). Quantitative Real-Time PCR analysis was performed as previously described using the 
appropriate primers (Boucneau et al., 2005). Western blot analysis using 20 µg of protein was performed 
according to standard procedures using polyclonal anti-neurofibromin antibody NF1(D) sc-67, NF1(N) sc-68, 
cyclin D1 (M-20) sc-718 (Santa Cruz Biotechnology, CA, USA), phospho-p42/44 MAP kinase (Thr202 / Tyr204) 
(Cell Signaling Technology), and anti-α-tubulin antibody (Sigma, St Louis, MO, USA). Immunocomplexes were 
visualized by chemiluminescence using the ECL+Plus system (Amersham, Uppsala, Sweden). For cell cycle 
analysis cells were harvested and resuspended in 1 ml PBS (Ca++ / Mg++ free, pH 7.4) and fixed overnight with 
3 ml cold 70% ethanol at 4°C. After washing in PBS, 50 μg/ml propidium iodide in PBS and 10 μg/ml RNase A 
were added and incubated for 30 min at 37°C. Cell cycle analysis was performed by flow cytometry (FACS 
Calibur; Becton Dickinson). The proportion of cells in the G1, S, G2/M phases of the cell cycle was estimated using 
Cylchred software (University of Wales, College of Medicine). MTS cell proliferation assay was performed using 
the CellTiter 96® Aqueous One Solution Cell Proliferation Assay kit (Promega, Madison, WI, USA). Twenty 
microliters of CellTiter 96® Aqueous One Solution reagent (MTS tetrazolium compound) was added to each well 
of a 96-well culture plate containing siNF1 (100 nM) electroporated primary human epidermal melanocytes in 100 
µL of culture medium. The plate was incubated for 2h at 37°C in 10% CO2. The absorbance at 492 nm was 
measured using a Labsystems MultiSkan RC microplate reader. 
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Figure legends 
Figure 1. Effects of NF1 gene (product) suppression on cell proliferation and cell cycle distribution. (a) 
Quantitative real-time PCR analysis of NF1 mRNA expression in control (siSCRAMBLE) siRNA (black bar) and 
siNF1 electroporated epidermal melanocytes (white bars; 2d, 4d, 6d and 8d). Data are expressed as mean +/- 
SEM of 3 replicates. (b) 6-10% PAGE immunoblot analysis of whole-cell lysates extracted from control 
(siSCRAMBLE) siRNA and siNF1 electroporated epidermal melanocytes after 2d (lane 1 and 2), 4d (lane 3 and 
4), 6d (lane 5 and 6), 8d (lane 7 and 8). Neurofibromin was detected with an anti-neurofibromin C-terminal 
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antibody NF1(D) and N-terminal antibody NF1(N). Phospho-p44/42 MAPK (pERK) and cyclin D1 were detected 
with the appropriate antibodies. α-tubulin was used as loading control. (c) Effect of neurofibromin suppression on 
melanocyte proliferation after 2d, 4d, 6d and 8d was assessed by the MTS assay. Black bars represent control 
(siSCRAMBLE) siRNA electroporated melanocytes, white bars represent siNF1 electroporated melanocytes. Data 
are expressed as mean +/- sem of 2 replicates and are normalized to controls (d) Cell cycle analysis progression. 
Cells were harvested after 2d, 4d, 6d and 8d, fixed and stained for DNA content. The distribution (%) of cells in 
G1, S and G2 phase of the cell cycle are indicated. 
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Identification of amyloid precursor protein as novel neurofibromin interaction partner: 
expanding the role of neurofibromin in epidermal melanocytes and 
implications for NF1 etiopathology  
 
Chapter 4 | Neurofibromin – APP interaction in epidermal melanocytes 
 
116 
  
 
Article V 
 
Neurofibromatosis type 1 protein and amyloid precursor protein interact in normal human melanocytes 
and colocalize with melanosomes. 
 
Sofie De Schepper #, Joachim Boucneau #, Wendy Westbroek, Mieke Mommaas, Ludwine Messiaen, Jean-Marie 
Naeyaert and Jo Lambert. J Invest Dermatol 126(3): p.653-659 (2006) (# first two authors equally contributed). 
 
 
Copublished in the same issue (commentary article in J Invest Dermatol 126(3): p.547-550) and based on our 
study, Diwakar and Hornyak discussed the association between APP and neurofibromin, and their localization to 
melanosomes. They postulated and confirmed the potential importance of this association in the etiopathology of 
CALMs. 
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 General discussion and 
future perspectives 
Neurofibromatosis type 1 (NF1) is one of the most common neurocutaneous cancer predisposition syndromes 
known to humans and affects primarily neural crest-derived cells and tissues (Poyhonen et al., 1997). Fifty 
percent of NF1 patients have sporadic NF1 gene mutations, while the other half has a familial history for the 
disease (Friedman et al., 1999). The NF1 gene is approximately 350 kb of genomic DNA, generates a transcript 
of around 11-13 kb, codes for a protein (neurofibromin) of 2818 aa and is ubiquitously expressed (Li et al., 1995; 
Bernards et al., 1992; Marchuk et al., 1991).  
NF1 patients present with typical hyperpigmentary cutaneous (café-au-lait macules [CALMs] and intertriginous 
ephelides) and hyperpigmentary non-cutaneous lesions (iris Lisch nodules) (see chapter 1 – article I), which 
could argue for a specific role of the NF1 gene (product) in regulating differentiation (melanin synthesis, 
melanosome biogenesis / transport, melanosome transfer) and / or proliferation of the pigment producing cell, the 
melanocyte. The vast majority of NF1 research has been mainly focused on the (peripheral nerve sheet) 
Schwann cell as central (neoplastic) cell involved in the etiopathogenesis of neurofibromas. These lesions pose a 
heavy physical and psychosocial burden, increasing the urge for an effective therapy. However, a closer look into 
the role of the (epidermal) melanocyte in other (more bearable) NF1 disease manifestations (e.g. CALMs) will 
only help in extending our knowledge of the function of this large tumor suppressor gene (product). The only 
major cellular function of neurofibromin that has been studied in detail and has been the primary link to its tumor 
suppressor properties, is the GTPase activating protein (GAP) function which can be ascribed to a centrally 
located region, called the GAP-related domain (GRD) (Xu et al., 1990).  
 
 
[I] NF1 haploinsufficiency: when half is enough ... 
 
An elegant approach – which has been applied in this study – to investigate the functional role of a gene and its 
corresponding protein in a particular (human) cell type, is to work with an in vitro cell system in which the gene of 
interest is mutated, and consequently produces an aberrant, reduced or absent protein. A potential mechanism 
that explains an abnormal phenotype arising as a result of the mutation of one allele (heterozygosity) is that of 
haploinsufficiency, i.e. the situation in which the total level of a gene product produced by a cell is about half of 
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the normal baseline levels and is not sufficient to permit the cell to function normally. The role of 
haploinsufficiency as a phenomenon of gene dosage reduction and sensitivity is often underestimated when it 
comes to its contribution to tumorigenesis (Santarosa and Ashworth, 2004; Wu et al., 2005). In many cases, 
heterozygous loss-of-function mutations can lead to the generation of tumors (in a haploinsufficiency context) that 
are frequently of later onset and less severe than the corresponding tumor carrying the homozygously mutated 
gene (e.g. p27, p53, Dmp1), while haploinsufficiency in other tumor suppressor genes is associated with early 
stages of the disease (e.g. hamartomatous polyp formation; PTEN, Smad4, Lkb1) (Quon and Berns, 2004; Cook 
and McCaw, 2000). These haploinsufficiency effects could be applied to e.g. neurofibroma formation in NF1 
patients which starts to emerge around puberty and early adolescence (later onset) (see chapter 1). However, 
the question still remains as to whether the increased occurrence and presence of CALMs and hamartomatous 
iris Lisch nodules in NF1 (see chapter 1) can also be explained by NF1 haploinsufficiency, as these clinical 
manifestations are congenital or show an early onset. Some groups have suggested that embryological 
melanoblast migration defects (perhaps due to altered growth / survival / motogenic factor sensitivity) could lie at 
the basis of CALM etiopathogenesis in NF1 (reviewed in De Schepper et al., 2005). 
 
When our present study was initiated, nothing was known on the effects of NF1 heterozygosity on total cellular 
gene / transcript expression. Congenital autosomal mutations of a tumor suppressor gene allele can induce 
profound cell and tissue-specific biological effects which are in part the result of altered gene expression and 
function. Loss-of-function mutations often provide clues to the role genes play in a cell or organism. How does 
NF1 heterozygosity (and consequently haploinsufficiency of the NF1 gene locus) affects the melanocyte and can 
NF1 heterozygosity tell us something more on the function of neurofibromin? To address this question, we used 
an in vitro NF1 heterozygous (NF1+/-) primary human epidermal melanocyte system consisting of cells that were 
isolated and cultured from NF1 patient skin biopsies (lesional and non-lesional skin). This approach can be 
considered as an ultimate model system to learn more about the role of the NF1 gene in a cell-specific manner. 
We performed high-throughput cDNA microarray analysis to compare the effects of a mutated NF1 allele on the 
expression of the melanocytic transcriptome between NF1 wild type (NF1+/+) melanocytes and NF1 heterozygous 
(NF1+/-) melanocytes (see chapter 2). The particular experimental loop design used in this study enabled us to 
search for possible melanocyte-intrinsic lesional type-dependent effects (normally pigmented skin melanocytes 
versus hyperpigmented café-au-lait skin melanocytes). Microenvironmental effects due to heterotypic cellular 
interactions in the epidermal region and / or due to signaling through paracrine cytokine networks are not 
considered in this in vitro setup. Our data unraveled the fact that gene expression was mainly affected by 
genotypic differences (one normal – one mutated versus two normal NF1 alleles). The differential expression 
mainly involved genes regulating cell proliferation and cell adhesion. Several transcription factor genes, involved 
in melanocyte-lineage development, were downregulated in NF1+/- melanocytes. These were shown to be 
involved in the cis-regulated transcriptional regulation of dopachrome tautomerase (DCT) expression (see also 
chapter 1), a major melanocytic biomarker gene.  
 
It has already been demonstrated in vitro that p21Ras-GTP levels do not alter in a NF1 heterozygous melanocytic 
background (Griesser et al., 1995) and that these melanocytes strangely enough showed a reduced proliferative 
capacity (Kaufmann et al., 1991). In light of gene dosage sensitivity due to haploinsufficiency it was interesting to 
investigate if reduction in NF1 gene expression (e.g. by post-transcriptional downregulation) in normal 
melanocytes had a (similar) effect on melanocyte proliferation. We artificially suppressed NF1 gene (product) 
expression by siRNA-mediated RNA interference (see chapter 3). Primary human epidermal melanocytes were 
electroporated with specific siRNA molecules targeting the NF1 gene. Functioning as a true tumor suppressor 
protein, neurofibromin is able to decrease cellular proliferation by inhibiting its downstream effector p21Ras. 
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However, in our study melanocytes did not show any proliferative changes upon reduction of endogenous 
neurofibromin, which was reflected by a lack of induction of phosphorylated ERK (p21Ras downstream effector) or 
cyclin D1 expression. The cell cycle profile also remained unchanged. These results suggest that neurofibromin is 
not the major regulator of melanocyte proliferation, at least in vitro. 
 
Our work has primarily focused on the role of neurofibromin in an in vitro melanocytic cell system. We can only 
speculate on how a multicellular-multifactorial microenvironment influences the functional properties of 
neurofibromin in a single cell-type and how a cell-specific response propagates in its immediate surroundings. 
The contribution of genetic and / or epigenetic changes in non-tumor cells to tumorigenesis has only begun to be 
appreciated recently. Haploinsufficiency of the NF1 gene is required for tumor formation by NF1 homozygous 
mutant cells. A tractable mouse model of neurofibromas does exist and appears to be a usefull tool to study the 
role of Nf1 gene (product) in the context of heterotypic cell interactions in vivo. These conditional knock-out mice, 
which have a Nf1 heterozygous genotypic background essential for tumor formation, contain a floxed Nf1 allele 
that can be deleted by a Cre-recombinase transgene under the control of the Schwann cell-specific promotor, 
Krox-20 (Zhu et al., 2002). In this way the cell type (i.e Schwann cell) in which Nf1 gets deleted can be controlled, 
a situation that is not the case in chimeric mouse models that are partially composed of Nf1-/- cells (Cichowski et 
al., 1999). Nf1+/- mast cells were suggested as having a crucial role in progression of neurofibroma formation 
(ECM remodeling and angiogenesis) as it was shown that neurofibromin-deficient Schwann cells secreted 
elevated levels of stem cell factor (SCF) as migratory stimulus for mast cells within the tumor environment (Yang 
et al., 2003; Wu et al., 2005). In mice it has been shown that primary Nf1+/- astrocyte cultures failed to 
demonstrate a cell-autonomous growth advantage unless they were cocultured with C17 neuronal cells. This cell-
context dependent increase in astrocyte proliferation was suggested to be sufficient for the development of 
astrocyte growth abnormalities in patients with NF1 (Gutmann et al., 1999). Whether there is a similar mechanism 
working in the epidermis that might explain the increased number of melanocytes in NF1 patients (see chapter I – 
article 2) needs to be further investigated. The observation that mono-cultures of NF1+/- melanocytes do not show 
this cell growth advantage (Kaufmann et al., 1991; own observations) supports this cell-context dependency. In 
vivo, epidermal melanocytes are indeed under the control of autocrine and paracrine cytokine networks and this 
cell context / cytokine dependent interaction between epidermal keratinocytes, dermal fibroblasts and epidermal 
melanocytes, is probably playing a major role in (hyper)pigmentary disorders (Imokawa et al., 2004). 
Hypersensitivity for growth factors (e.g SCF) due to Nf1 haploinsufficiency has already been demonstrated in 
mouse melanocytes and mast cells (Ingram et al., 2000). A relevant mouse model for CALMs (to study the role of 
neurofibromin in melanocytes in a cell context-dependent environment) does not exist and is probably difficult and 
perhaps impossible to generate. In order to study the functional role of neurofibromin in a more controlled 
physiological environment resembling the natural epidermis (mimicking heterotypic intercellular interactions), an 
initial 2-dimensional coculture system of epidermal melanocytes and keratinocytes could be used (Lei et al., 
2002). We could introduce mixtures of NF1 heterozygous melanocytes and / or keratinocytes to study growth 
factor sensitivity (e.g. SCF) and its cellular effects in a haploinsufficient environment. This could teach us more on 
the exact role of neurofibromin in epidermal homeostasis. It has been shown that Nf1 haploinsufficiency increases 
mast cell proliferation and survival upon SCF treatment (Ingram et al., 2000). To further increase the epidermal 
resemblance, reconstructed skin could be an excellent laboratory working tool to address the question which 
genetic and epigenetic factors are potentially involved in normal epidermal homeostasis in general and more 
specific in the regulation of the epidermal melanocyte. CALMs are not considered as neoplastic or hyperplastic 
lesions as the basic tissue organisation of the epidermis remains intact compared to normal skin and does not 
present with the cellular heterogeneity of the complex tissue mass in a neurofibroma that once was a normal 
peripheral nerve. An attempt has already been made to construct a pigmented skin equivalent to study 
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hyperpigmentation in CALMs. However, this model for congenital hyperpigmentary disorders was insufficient due 
to the lack of terminal differentiation of keratinocytes (Okazaki et al., 2005). The recent progress in the field of 
epithelial culture techniques has allowed the development of culture systems in which reconstructed epidermis 
shows characteristics of morphological differentiation similar to those seen in vivo. This skin equivalent is the 
dead de-epidermized dermis (DDD) on which a mixture of keratinocytes, melanocytes, fibroblasts and / or mast 
cells are seeded (Rehder et al., 2004). Albeit, these skin equivalent models could be an excellent tool for the 
evaluation of the effects of several (physiological) proliferation and differentiation promoting agents on the 
function of neurofibromin, not only in the melanocyte but also in its interplay with the surrounding 
microenvironment. 
 
 
[II] Protein-protein interactions: neurofibromin in the spotlight 
 
Using yeast-two-hybrid analysis, co-immunoprecipitation studies and subcellular / ultrastructural confocal laser 
scanning and immuno-electron microscopy, we have identified and localized a novel protein-protein interaction 
between amyloid precursor protein (APP) and the GRD of neurofibromin (see chapter 4). Recent studies have 
been interpreted as consistent with the idea that APP serves as a kinesin-1 cargo receptor and plays a role in the 
anterograde movement of membranous (vesicular) cargos along microtubules (Kamal et al., 2000; Lazarov et al., 
2005). We showed that both APP and neurofibromin were able to colocalize with melanosomes and 
demonstrated that this association with melanosomes was lost in NF1+/- melanocytes. This is an interesting 
observation in light of the hyperpigmentary defects seen in NF1 and suggests a specific role for neurofibromin in 
the regulation of melanosome transport / biogenesis in human epidermal melanocytes. The biological significance 
and interaction details of the neurofibromin–APP association need to be further clarified as the functional role of 
this interaction in specific cellular / tissue systems is currently unknown: 
 
• Using site-directed mutagenesis (introducing substitution mutations) in combination with yeast-two-
hybrid analysis and reporter gene assays, we can modify, screen and narrow down the GRD for key 
residues mediating the interaction with APP. The reverse can be done to find the direct binding sites in 
APP. Screening of a (large) cohort of NF1 patients with known missense mutations in their GRD can 
also help us determine the direct binding site mediating the interaction with APP. 
 
• As we suggested that the interaction is potentially involved in the regulation of vesicle (e.g. melanosome) 
transport / biogenesis, this complex could have analogous functional properties in other vesicle 
transporting / secreting (neural crest-derived) cell types like neurons. A small percentage of NF1 patients 
present with mental redardation and other cognitive defects that could argue for an important role of this 
protein complex in neurotransmitter transport and release towards synaptic membranes. Interestingly, 
the motor protein kinesin-1 has been shown to be a link between NF1 – as a common neurological 
disorder – and Alzheimer’s disease (Hakimi et al., 2002). Our finding that APP, which functions as a 
kinesin-1 cargo receptor, shows an interaction with neurofibromin not only strengthens this link but could 
provide basic biological insights into vital cellular processes (e.g. protein trafficking). 
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The large-scale identification of novel neurofibromin interacting or associating proteins will help extend our 
knowledge on the cellular function of this large tumor suppressor. State-of-the art proteomics techniques for the 
extensive analysis of subcellular localization and distribution of neurofibromin in subcellular structures could help 
us discover new biological insights and would open up many new ways for future investigations: 
 
• By controlled permeabilisation and homogenization of melanocytes, followed by subcellular (organellar) 
fractionation using a combination of centrifugation approachtes (equilibrium density gradient), we can 
determine the amount of neurofibromin in specific organellar fractions (mitochondria, ER, nucleus, Golgi, 
melanosomes, etc.). In these purified organellar fractions we could search for organelle-typic 
neurofibromin interacting / associating proteins. This would advance our understanding of the role of 
neurofibromin. The development of isoform-specific antibodies against neurofibromin would greatly 
enhance the resolution of subcellular neurofibromin distribution and function.  
 
• In combination with high-resolution proteomics (2-dimensional gel electrophoresis (2DGE) followed by 
mass spectrometry-based protein identification methods) we could map the intracellular and / or 
interorganellar localization and transport of different neurofibromin isoforms and their specifc interaction 
partners during key cellular events (e.g. melanosome biogenesis-transport-transfer, mitosis, apoptosis, 
etc.), under different physiological states, and in normal and diseased cells.  
 
• Placing protein-protein interactions in a more physiological context, specifically with regard to 
(post)translational modification-mediated interactions (e.g. due to phosphorylation), could be done using 
the mammalian-two-hybrid system (MAPPIT; Mammalian Protein-Protein Interaction Trap; Eykerman et 
al., 2001), which allows to study protein interactions in mammalian cell types (in situ) in stead of a 
eukaryotic yeast background.  
 
Clearly, the time has come for an organized effort to characterize subcellular proteomes in different types of 
human cells. In order to obtain a global comprehensive picture of the function of a gene product these new 
technologies will be invaluable tools. The use of proteomics to characterize proteins and their relation to 
subcellular organelles will provide new functional insights, and these data will become more complete and 
convincing when proteomic analyses will be combined with protein localization and protein knock-down studies. 
Perhaps neurofibromin will be in the spotlight soon ... 
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 Summary 
Neurofibromatosis type 1 (NF1) is one of the most common genetic neurocutaneous disorders with a prevalence 
of approximately 1 in 3500 individuals. NF1 affects primarily neural crest-derived cells and tissues, and patients 
develop both benign and malignant tumors at an increased frequency. Affected individuals present with a variety 
of clinical signs of which cutaneous neurofibromas, café-au-lait macules and iris Lish nodules are cardinal 
hallmarks of the disease. Advances in the understanding of the molecular pathogenesis of clinical features in NF1 
have resulted from the identification of the NF1 tumor suppressor gene and the elucidation of its function. The 
only extensively characterized functional domain is the centrally located GAP-related domain (GRD). Being a 
large protein, neurofibromin harbors several other (unidentified) functional domains, and dito cellular functions, 
which could extend our knowledge of how mutations of the NF1 gene cause specific NF1 disease manifestations. 
An interesting observation in NF1 is the presence of specific hyperpigmentary cutaneous (café-au-lait macules, 
intertriguinous ephelides) and hyperpigmentary non-cutaneous lesions (iris Lisch nodules), which could argue for 
a specific role of neurofibromin in regulating cellular differentiation and / or proliferation of the pigment producing 
cell, the melanocyte. 
 
The major goal of this work was to gain more insight into the functional role of the NF1 gene and its 
corresponding gene product neurofibromin in primary human epidermal melanocytes. 
 
Initially we investigated the role of the NF1 gene by assessing the effect of NF1 gene heterozygosity on the 
expression of the melanocytic transcriptome. Using cDNA microarray analysis we compared human NF1 
heterozygous (NF1+/–) epidermal melanocytes to NF1 wild type (NF1+/+) epidermal melanocytes, both being 
isolated and cultured from normally pigmented skin and hyperpigmented lesional café-au-lait skin. We found that 
gene expression was affected most strongly by genotype and less so by lesional type, probably due to in vitro 
conditions. A high number of transcription factor genes, among which a specific subset important in melanocyte 
lineage development, were downregulated in a cis-regulatory network governing the activation of the melanocyte-
specific dopachrome tautomerase (DCT) gene. Although the results presented have been obtained with a 
restricted number of patients (one NF1 patient and one control) and using cDNA microarrays that may limit their 
interpretation, the data nevertheless addresses for the first time the global effect of a heterozygous NF1 gene on 
the expression of the human melanocyte transcriptome and has generated several interesting candidate genes 
helpful in elucidating the etiopathology of café-au-lait macules in NF1 patients. 
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In light of gene dosage sensitivity due to haploinsufficiency it was of course interesting to see if reduction in NF1 
gene expression in normal melanocytes had an effect on melanocyte proliferation. We artificially suppressed NF1 
gene (product) expression by siRNA-mediated RNA interference. Primary human epidermal melanocytes were 
electroporated with specific siRNA molecules targeting the NF1 gene. Functioning as a true tumor suppressor 
protein, neurofibromin is able to decrease cellular proliferation by inhibiting its downstream effector p21Ras. 
However, in our study melanocytes did not show any changes in cell proliferation upon reduction of endogenous 
neurofibromin, which was reflected by a lack of induction of phosphorylated ERK (p21Ras downstream effector) or 
cyclin D1 expression. The cell cycle profile also remained unchanged. These results suggest that neurofibromin 
does not play a major role in regulation of melanocyte proliferation, at least in vitro. 
 
The discovery of novel neurofibromin interacting proteins can reveal new functional properties of this large tumor 
suppressor protein. We identified and characterized amyloid precursor protein (APP) as a new neurofibromin-
associating protein in primary human epidermal melanocytes. Using yeast two hybrid analysis against a brain 
cDNA library, we identified a novel interaction between APP and the GRD of neurofibromin. This interaction was 
further analyzed in human melanocytes and confirmed by immunoprecipitation and colocalization studies. In 
addition, we observed colocalization of APP and neurofibromin with melanosomes, the melanin-containing 
organelles of the melanocyte. APP has been proposed to function as a vesicle cargo receptor for the motor 
protein kinesin-1 in neurons. This colocalization of APP and neurofibromin with melanosomes was lost in 
melanocytes obtained from a severly affected NF1 patient. We suggest that a tripartite complex between APP, 
neurofibromin, and melanosomes might be important in melanosome biogenesis, transport and transfer. 
 
In conclusion, this study has demonstrated the use of several molecular approaches (large scale – small scale) to 
investigate and extend the role of the NF1 gene and its corresponding protein neurofibromin in primary human 
epidermal melanocytes. Gaining better insight in the functional role of a (defective) gene (product) adds to a 
better understanding of the etiology of NF1 and to the progress in treatment of these non-life threatening 
hyperpigmentary anomalies. 
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 Samenvatting 
Neurofibromatose type 1 (NF1) behoort tot één van de meest voorkomende genetische, neurocutane ziekten met 
een prevalentie van 1 op 3500 individuen. Voornamelijk cellen en weefsels afkomstig van de neurale lijst zijn 
aangetast en patiënten ontwikkelen met een verhoogde frequentie zowel goed- als kwaadaardige tumoren. 
Getroffen personen vertonen een verscheidenheid aan klinische tekens waarvan cutane neurofibromen, café-au-
lait vlekken en Lisch nodules de voornaamste kenmerken zijn van de ziekte. Dankzij de ontdekking van het NF1 
tumor suppressor gen en de opheldering van zijn functie is vooruitgang geboekt in onze kennis van de 
moleculaire pathogenese van deze klinische kenmerken in NF1. Het enige functionele domein dat in detail is 
gekarakteriseerd, is het centraal gelegen GAP-related domain (GRD). Als groot eiwit heeft neurofibromine nog 
verschillende andere (niet geïdentificeerde) functionele domeinen, en dito cellulaire functies, die onze kennis 
kunnen uitbreiden van hoe mutaties in het NF1 genproduct aanleiding geven tot specifieke NF1 ziektebeelden. 
Een interessante waarneming in NF1 is de aanwezigheid van specifieke gehyperpigmenteerde cutane (café-au-
lait vlekken, sproeten in oksels en lies) en gehyperpigmenteerde niet-cutane letsels (Lisch nodules in de iris), die 
een argument zouden kunnen zijn voor de rol van neurofibromine als regulator van cellulaire differentiatie en / of 
proliferatie van de pigment producerende cel, de melanocyt. 
 
Met deze studie wilden we meer inzicht verwerven in de functionele rol van het NF1 gen en zijn corresponderend 
genproduct neurofibromine in primaire humane epidermale melanocyten. 
 
Initiëel hebben we de rol van het NF1 gen onderzocht door de effecten na te gaan van NF1 heterozygositeit op de 
expressie van het melanocytair transcriptoom. Door middel van cDNA microarray analyse vergeleken we 
gekweekte humane NF1 heterozygote melanocyten (NF1+/-) met NF1 wild type (NF1+/+) melanocyten, die zowel 
uit normaal gepigmenteerde als gehyperpigmenteerde huid van een lesionele café-au-lait vlek geïsoleerd en 
gekweekt waren. We zagen dat een genexpressie het meest beïnvloed werd door het genotype, niet zozeer door 
het lesionele huidtype waaruit de melanocyten gekweekt waren. Een grote hoeveelheid transcriptiefactoren 
vertoonden een verlaagde expressie, waaronder een specifieke subset die belangrijk is in de ontwikkeling van de 
melanocyt, en waren betrokken in een cis-regulerend netwerk dat instond voor de activatie van het melanocyte-
specifieke gen dopachrome tautomerase (DCT). Hoewel de resultaten afkomstig zijn van een beperkt aantal 
patiënten (één NF1 patiënt en 1 gezonde controle) in combinatie met cDNA microarray analyse die als limiterend 
Chapter 6 | Summary – Samenvatting – Résumé 
 
138 
zou kunnen aanzien worden, worden hier toch voor de eerste keer de effecten van NF1 heterozygositeit 
nagegaan op de expressie van het melanocytair transcriptoom. Hierbij zijn tevens een interessante set van 
kandidaatgenen naar voor gekomen die zouden kunnen meehelpen in de opheldering van de etiopathogenese 
van café-au-lait vlekken in NF1 patiënten. 
 
In het licht van gendosage gevoeligheid die te wijten is aan haploinsufficientie, was het natuurlijk interessant om 
na te gaan of reductie in NF1 genexpressie in normale melanocyten een effect had op proliferatie van 
melanocyten. Kunstmatig onderdrukten we de expressie van het NF1 gen(product) door middel van siRNA-
gemedieerde RNA interferentie. Primaire humane epidermale melanocyten werden geëlectroporeerd met NF1 
gen-specifieke siRNA moleculen. Als een echt tumor suppressor eiwit is neurofibromine in staat celproliferatie te 
verminderen door zijn downstream effector p21Ras te inhiberen. In onze studie daarentegen zagen we geen 
enkele verandering in de celproliferatie na reductie van endogeen neurofibromine, en dat werd weerspiegeld door 
een gebrek aan inductie van ERK phosphorylatie of cycline D1 expressie. Het profiel van de celcyclus bleef ook 
onveranderd. Deze resultaten suggereren dat neurofibromin geen grote rol speelt in de regulatie van melanocyt 
proliferatie, tenminste in vitro. 
 
De ontdekking van nieuwe neurofibromine-interagerende eiwitten kan nieuwe functionele eigenschappen van dit 
groot tumor suppressor eiwit ontsluieren. Wij hebben het amyloid precursor proteïne (APP) geïdentificeerd en 
gekarakteriseerd als een nieuw neurofibromine interagerend eiwit in primaire humane epidermale melanocyten. 
Via ‘yeast two hybrid’ analyse tegen een ‘brain’ cDNA bibliotheek, identificeerden we een nieuwe interactie tussen 
APP en de GRD van neurofibromine. Deze interactie werd verder geanalyseerd in humane melanocyten en 
bevestigd met co-immunoprecipitatie en colokalisatie studies. Daarenboven observeerden we een colokalisatie 
tussen APP en neurofibromine met melanosomen. APP wordt in neuronen gezien als vesikel cargo receptor voor 
het motoreiwit kinesin-1. Dergelijke colokalisatie tussen APP en neurofibromine met melanosomen was verloren 
in melanocyten afkomstig van de normale huid van een NF1 patiënt. Wij suggereren dat een tripartiet complex 
tussen APP, neurofibromine en melanosomen van belang kan zijn in melanosome biogenese, transport en 
transfer. 
 
Tot slot kunnen we stellen dat we in deze studie verschillende moleculaire benaderingen (large scale – small 
scale) hebben toegepast om de rol van het NF1 gen en zijn overeenkomstig eiwit neurofibromine in primaire 
humane epidermale melanocyten te onderzoeken en uit te breiden. Een beter inzicht verschaffen in de 
functionele role van een (defect) gen(product) kan ons alleen maar helpen in een betere kennis van de etiologie 
van NF1, en kan bijdragen aan de vooruitgang in de behandeling van deze niet-levensbedreigende gehyperpig-
menteerde lesies. 
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 Résumé 
La Neurofibromatose de type 1 (NF1) est une des maladies génétiques neurocutanées les plus communes 
touchant 1 individu sur 3500. La maladie NF1 affecte de manière prédominante les cellules et les tissus dérivés 
de la crête neuronale, et les patients développent des tumeurs bénignes et malignes à une fréquence augmentée. 
Les individus affectés présentent une variété de signes cliniques dont les neurifbromes, les taches café-au-lait et 
les nodules de Lisch caractérisant la maladie. L’avance des connaissances de la pathogénie moléculaire des 
caractéristiques cliniques de NF1 résultent de l’identification du gène suppresseur de tumeur NF1 et sa fonction. 
Le seul domaine fonctionnel bien caractérisé est le domaine nommé GRD (GAP related domain), situé au centre 
du gène. Etant une protéine de grande taille, la neurofibromine contient plusieurs autres domaines fonctionnels 
non-identifiés, ainsi que des fonctions cellulaires, qui pourraient nous amener à mieux comprendre comment les 
mutations dans le gène NF1 peuvent causer les manifestations spécifique à la maladie. Une observation 
intéressante dans NF1 est la présence des lésions hyperpigmentées cutanées (les taches café-au-lait, les taches 
de rousseur axillaires / inguinales) et les lésions hyperpigmentées non-cutanées (les nodules de Lisch). Celles-ci 
suggèrent un rôle spécifique de la neurofibromine dans le contrôle de différentiation et de prolifération de la 
cellule contenant la mélanine, le mélanocyte. 
 
Le but majeur de cette étude était mieux comprendre le rôle fonctionnel du gène NF1 et de son produit, la 
neurofibromine, dans les melanocytes primaires issus d’épiderme humain. 
 
Nous avons commené par examiner le rôle du gène NF1 en évaluant l'effet de hétérozygosité du gène NF1 sur 
l'expression du transcriptome mélanocytique. Utilisant l'analyse des microarrays d’ADNc, les melanocytes 
primaires issus d’épiderme humain présentant une hétérozygosité du gène NF1 (NF1+/–) ont été comparés à des 
melanocytes primaires issus d’épiderme humain contenant un gène NF1 sauvage (NF1+/+). Les deux types de 
mélanocytes ont été isolés et cultivés hors de peau pigmentée normale et de peau hyperpigmentée lesionelle 
(des taches café-au-lait). Nous avons trouvé que l’ expression du gène était fortement déterminée par le génotype 
et moins par le type de lesion, probablement liés aux conditions in vitro. Un grand nombre de gènes de facteur de 
transcription, parmi lesquels un (sous-)ensemble spécifique important au développement du lignage 
melanocytaire, ont été réprimés dans un réseau cis-régulatoir gouvernant l'activation du dopachrome tautomerase 
(DCT) qui est un gène mélanocytaire spécifique. Bien que les résultats présentés ont été obtenus dans un 
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nombre limité de patients (un patient NF1 et un patient contrôle) et en utilisant des microarrays d’ADNc, pouvant 
limiter l’interprétation des données, celles-ci ont adressé pour la première fois l'effet global de hétérozygosité du 
gène NF1 sur l'expression du transcriptome mélanocytaire humain et ont démontré les produits de plusieurs 
gènes candidats intéressants pouvant aider à  expliquer l’étiopathologie des taches café-au-lait dans les patients 
NF1. 
 
Tenant compte de la sensibilité de dosage du gène en raison de la haplo-insufficiance, il était intéressant de voir 
si une réduction de l’expression du gène NF1 dans des melanocytes normales avait un effet sur la prolifération 
des melanocytes. Pour cela nous avons éliminé artificiellement l’expression du (produit de) gène NF1 par l’ARN 
interférence medié par les siRNAs. Des melanocytes primaires issus d’épiderme humain ont été electroporées 
avec des molécules de siRNA spécifiques ciblant le gène NF1. Fonctionnant comme une protéine suppresseur de 
tumeur, la neurofibromine pouvait diminuer la prolifération cellulaire en inhibant son effecteur p21Ras dans 
plusieurs lignes cellulaires (dérivantes des patients NF1). Cependant, les melanocytes n'ont pas montrés de 
changement dans leur prolifération cellulaire après réduction de la neurofibromine endogène et ceci se réflétait 
par un manque d'induction de phosphorylation de la protéine ERK (effecteur de p21Ras) et de la protéine cyclin 
D1. Le profil du cycle cellulaire restait également inchangé. Ces résultats suggèrent que la neurofibromine ne 
joue pas de rôle majeur dans le règlement de prolifération des melanocyte, tout du moins in vitro. 
 
La découverte des nouvelles intéractions protéine-protéine avec la neurofibromine pourraient révéler de nouvelles 
propriétés fonctionnelles de cette protéine suppresseur de tumeur. Nous avons identifié et charactérizé une 
nouvelle intéraction protéine-protéine entre la protéine précurseur de la protéine beta-amyloid (APP) et la 
neurofibromine dans les melanocytes primaires issus d’épiderme humain. En utilisant le système de deux 
hybrides en levure dans une bibliothèque d’ADNc du cerveau humain, nous avons identifié une nouvelle 
intéraction protéine-protéine entre l’APP et la GRD de la neurofibromine. De plus, cette intéraction a été analysée 
dans les mélanocytes humains et confirmée (par rapport à des) dans des études de coprécipitation 
immunologique et colocalisation. Nous avons égalament observé une colocalisation entre l’APP, la 
neurofibromine et les mélanosomes, qui sont les organelles mélanocytaires contenant de la mélanine.  L’APP a 
été proposée de fonctionner comme un récepteur de cargaison vésiculaire pour la protéine moteur kinésine-1 
dans les neurones. Cette colocalisation entre l’APP, la neurofibromine et les melanosomes était absente dans les 
melanocytes obtenus d'un patient NF1 gravement atteint. Nous suggérons qu'un complexe tripartite entre l’APP, 
la neurofibromine, et les melanosomes est important dans la biogenèse, le transport et le transfert 
mélanosomique. 
 
En conclusion, cette étude a démontré l'usage de plusieures approches moléculaires (large scale – small scale) 
pour examiner et étendre le rôle du gène NF1 et son produit du gène, la neurofibromine, dans les melanocytes 
primaires issus d’épiderme humain. Gagnant mieux la perspicacité dans le rôle fonctionnel d'un (produit du) gène 
(défectueux) ajoute à une meilleure compréhension de l'étiologie de NF1 et au progrès dans le traitement de 
cettes anomalies hyperpigmentées. 
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• Neurofibromatosis type 1 (NF1) gene (product) expression in normal and café-au-lait skin of healthy controls 
and NF1 patients. De Schepper, S., Boucneau, J., Naeyaert, J.M., Lambert, J. 12th European Society for 
Pigment Cell Research (ESPCR), Paris, France, 2004. 
 
• Is there a potential role for dermal mast cells in the hyperpigmentary mechanism of café-au-lait maculae in 
Neurofibromatosis type 1 patients? Boucneau, J., De Schepper, S., Naeyaert, J.M., Lambert, J. 34th 
European Society for Dermatological Research (ESDR), Vienna, Austria, 2004. 
 
• Gene expression profiling of cultured human NF1 heterozygous (NF1+/-) melanocytes reveals downregulation 
of a transcriptional cis-regulatory network mediating activation of the melanocyte-specific dopachrome 
tautomerase (DCT) gene. Boucneau, J., De Schepper, S., Vuylsteke, M., Van Hummelen, P., Naeyaert, 
J.M., Lambert, J. 11th European Neurofibromatosis Meeting, Göteborg, Sweden, 2005. 
 
• Second hit mutation analysis in melanocytes, keratinocytes and fibroblasts obtained from NF1 café-au-lait 
spots. De Schepper, S., Messiaen, L., Claes, K., Maertens, O, Boucneau, J., Naeyaert, J.M., Lambert, J. 
19th International Pigment Cell Conference (IPCC), Reston, Virginia, USA, 2005. 
 
• RNAi-induced suppression does not modulate the cell cycle in cultured primary human epidermal 
melanocytes. Boucneau, J., De Schepper, S., Van Gele, M., Naeyaert, J.M., Lambert, J. (will be presented 
by Lambert, J.). 67th Annual Meeting of the Society for Investigative Dermatology (SID), Philadelphia, 
Pennsylvania, USA, 2006. 
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Oral presentations 
 
• NF1 and melanocytes. 1st NF1 workshop: wetenschappelijke onderzoeksgemeenschap FWO Vlaanderen, 
Molecular and Cellular mechanisms in NF1, Leuven, Belgium, January 10th – 11th, 2005. 
 
• Neurofibromin interacts with amyloid precursor protein in normal human epidermal melanocytes and 
colocalizes with melanosomes: implications for NF1 etiopathology. 2nd NF1 workshop: wetenschappelijke 
onderzoeksgemeenschap FWO Vlaanderen, Molecular and Cellular mechanisms in NF1, Leuven, Belgium, 
December 21st – 22nd, 2005. 
 
Participation to meetings, congresses and workshops  
 
• Analis Confocal Microscopy Workshop, June 5th, 2003 (Ghent, Belgium) 
• Special Federation of Biochemical Societies (FEBS) meeting on Signal Transduction, July 3rd – 8th, 2003 
(Brussels, Belgium) 
• 3rd VIB MicroArray Users Group meeting, September 10th, 2003 (Leuven, Belgium) 
• 11th European Society for Pigment Cell Research (ESPCR) meeting, September 17th – 20th, 2003 (Ghent, 
Belgium) 
• Wetenschapsdag vakgroep Inwendige Geneeskunde, Universitair Ziekenhuis Gent, January 22nd, 2004 
(Ghent, Belgium) 
• Life – a ‘Nobel’ story – symposium, April 28th, 2004 (Brussels, Belgium) 
• 34th European Society for Dermatological Research (ESDR) meeting, September 9th – 11th, 2004 (Vienna, 
Austria) 
• 4th VIB MicroArray Users Group meeting, November 18th – 19th, 2004 (Jette, Belgium) 
• 11th European Neurofibromatosis meeting – Families and Professionals together, July 7th – 10th, 2005 
(Gothenborg, Sweden) 
• 1st NF1 workshop: wetenschappelijke onderzoeksgemeenschap FWO Vlaanderen, Molecular and Cellular 
mechanisms in NF1, January 10th – 11th, 2005 (Leuven, Belgium) 
• Wetenschapsdag vakgroep Inwendige Geneeskunde, Universitair Ziekenhuis Gent, January 20th, 2005 
(Ghent, Belgium) 
• 2nd NF1 workshop: wetenschappelijke onderzoeksgemeenschap FWO Vlaanderen, Molecular and Cellular 
mechanisms in NF1, December 21st – 22nd, 2005 (Leuven, Belgium) 
 
Grants – prizes – awards 
 
• ASBL Neurofibromatose: “Project concerning learning difficulties in NF1 patients” – September 2nd, 2003 
(financial credits: 1,000 euro) 
• ESDR Travel Grant 2004 (financial credits: 500 euro) 
• Reiskrediet Fonds voor Wetenschappelijk Onderzoek – Vlaanderen (FWO): “11th European Neurofibro-
matosis meeting – July 7th – 10th, 2005 (Gothenborg, Sweden) 
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Gent, 4 juli 2002. Na de proclamatie aan de faculteit Toegepaste 
Wetenschappen – ik had een extra jaar aanvullende studies in de 
informatica gevolgd – fietste ik langs de Karel Ledeganckstraat waar ik een 
jaar eerder afgestudeerd was als licentiaat in de Biotechnologie. Ik wist 
niet wat de toekomst mij zou brengen. Het onderzoeksvuur brandde 
blijkbaar nog steeds, weliswaar op een laag pitje. Toen, heel toevallig, 
bladerde ik enkele dagen later in het magazine ‘Gent Universiteit’ (editie 
mei – juni 2002) en las ik op pagina 22 de vacature die de volgende 4 jaar 
van mijn leven zou bepalen. 
 
Op 1 september 2002 vertrok de doctoraatstrein! 
 
We zijn vandaag 1 maart 2006, de trein is bijna 4 jaar aan het bollen en het 
eindstation is in zicht. 
 
Niettegenstaande de vermoeidheid zwaar de kop opsteekt (het neerschrijven en bundelen van 4 jaar werk gaat 
niet over één nacht ijs), wil ik hier toch de tijd nemen om iedereen te bedanken die ervoor heeft gezorgd dat de 
trein voortdurend op het juiste spoor bleef rijden en die heeft meegeholpen om op de gepaste tijdstippen de 
wissels te verzetten om de koers bij te sturen richting eindstation. 
 
Eerst en vooral wil ik mijn promotoren bedanken, prof. dr. Jean-Marie Naeyaert en prof. dr. Jo Lambert. Professor 
Naeyaert, ik ben u heel dankbaar dat ik de kans heb gekregen om in uw vakgroep wetenschappelijk onderzoek te 
mogen doen. De interdisciplinaire kruisbestuiving in de wetenschappen die u hoog in het vaandel draagt, en uw 
heldere kijk, gedrevenheid en kritische ingesteldheid heb ik enorm geäpprecieerd en werkten enorm motiverend. 
Jo, een grote dank gaat uit naar jou. In alle drukte ben je steeds bereid geweest tijd vrij te maken om de 
resultaten en de vorderingen van het onderzoek te bespreken. Ik ben vereerd dat ik heb mogen bijdragen aan de 
uitbouw van jullie onderzoeksgroep. Continue steun en vertrouwen in mijn onderzoek. Dank voor het secuur 
nalezen van dit werk en de nuttige tips en correcties. Bedankt voor alles, ik vond het een eer! 
 
Sofie (collega NF1 specialist), de eerste keer dat ik je heb ontmoet was tijdens de selectieronde voor kandidaten 
voor bovenstaande vacature. NF1 onderzoek was onze band. Ik heb de aangename samenwerking, je 
professionaliteit en collegialiteit enorm geäpprecieerd. Ik wens je heel veel succes met je doctoraat en de uitbouw 
van je verdere carrière. Het ga je goed! 
 
En waar zou ik gestaan hebben zonder de hulp van 2 uitmuntende laboranten van onze onderzoeksgroep. 
Bedankt Martine (‘Melanocyten te koop, volledige uitverkoop, wie moet er hebben!’), dankzij jou heeft de 
celcultuur alvast geen (of althans veel minder) geheimen meer voor mij. Jij zorgde er steeds voor dat allerhande 
huidcellen optimaal konden doorgroeien en dat wij nooit zonder ‘grondstoffen’ zaten voor experimenten. Marie-
Chantal, jij hield de labo’s draaiende en coördineerde de verhuis van onze met nieuwe naam voorziene 
onderzoeksgroep (DRU - Dermatology Research Unit) naar de Medical Research Building. Jij kon overal 
inspringen als er hulp nodig was. Bedankt voor alles. Ik wil ook Mireille, onze eerste post-doc, bedanken. Jij 
kwam pas later in onze research unit maar door je spontaniteit en gedrevenheid leek het alsof je er al van bij het 
begin bij was. Het was aangenaam om samen te werken en vele interessante discussies te voeren. Nog veel 
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succes met je project. ‘Dien UV lampe, ojje dadde aanzet, da bloast nogal é!’ Karolientje, ook jij zwoegde 
doorheen je doctoraat. Op het moment dat ik dit schrijf zit je in de States. Veel (wetenschappelijk) plezier en 
succes in Washington. Ook jij bent er bijna! En natuurlijk wil ik ook mijn andere collega’s doctoraatsstudenten 
bedanken, Barbara en Hilde, het was aangenaam samenwerken en veel succes in de toekomst. 
 
Ik bedank ook alle mensen van de dienst huidziekten (polikliniek 6) voor de aangename samenwerking en de 
hulp die ik van jullie heb gekregen voor grotere en kleinere probleempjes: Liliane, An, Anthoine, Rita, Sofie, 
Francine, Katia, Nanja ... Ook ons twee-koppige IT-team wil ik bedanken. Merci Peter voor alle hulp als het 
systeem het eens liet afweten. Bedankt Yves voor de software-technische inbreng in bepaalde artikels en de 
interessante discussies. De kunst van het parapente-vliegen, de beste windrichtingen en opstijghellingen zijn nu 
geen mysterie meer.  
 
Ik wil hier ook de collega’s van het labo Experimentele Cancerologie bedanken. Tot vóór de verhuis van onze 
onderzoeksgroep was ons labo daar ondergebracht. Bedankt Ancy, Olivier, Barbara, Lara, Veerle, Georges, Rik, 
Arlette voor de leuke tijd daar! Eveneens wil ik Anouk en Liesbeth bedanken voor hun vrijgemaakte tijd en hulp bij 
de confocale microscoop. Ann, Sarah en Peggy van de vakgroep Reumatologie, bedankt voor de introductie in de 
FACS-wereld en alle hulp daarbij.  
Een bijzondere dank voor de mensen met wie ik heb samengewerkt. Bedankt Paul Van Hummelen, Tom 
Bogaerts en Marnik Vuylsteke, dankzij jullie hebben we het kluwen microarray data kunnen ontwarren. Bedankt 
voor alle advies, tips en hulp! 
 
En ‘last but not least’ wil ik mijn ouders en broer bedanken. Ma, Pa, ‘Pierre’, jullie hebben mij altijd de vrijheid 
gegeven te kiezen en te doen wat ik wilde. Jullie waren mijn toeverlaat en steun in iets moelijkere tijden en jullie 
hebben me altijd aangemoedigd er 100% voor te gaan. Hoewel ik het misschien weinig liet blijken, ben ik jullie 
oneindig dankbaar. 
 
Bedankt iedereen,  
 
Joachim Gent, Juni 2006 
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